Advances in Cancer Treatment

がん治療のあゆみ
2016/第36回一般研究助成

36

公益財団法人 がん集学的治療研究財団

01*!%,#Translational Research$'./(-)%+%&"±úgtæaM¦¶úµI3XQC)

ß

ý

)



Ä³,Cúµ*N"èÝ"½UÞ|K5[L¨X"±úITõ

M@98ÁL¹BWZH4QC!±ªN"i_alrDúÀL`]AFÄ³LYCY´±°A"°

R"Ì:4Ñ"u%9D#´@Z"F¨«µ8WM®9^LçÈ@Z"7°µ.÷

ÆMly#«#!ô9Þ|K5[LKXQAF!zL"tæaM

Ä³,CúµN"DL Transla-

tional Research'TR(§]xJA"yWZF¿]!cµ.O¥ÇCY>JI")9^£"@^Mý³*L×ÃI:Y7°µ.÷Æ]«#nI:YáT)­K&I3XQAF!>M3ÛtæaIN")/~z{Lµ.÷ÆM_JAHlyI:YÄ³*]©Jâ¬AH:QAF!J>[9">Z9µ.÷
ÆL§¸AF®Ö|JÐ'$(@Z"ÜM°AI®ÿ\M«µ9SAQAF!EM¿"·~,+À",++MÄ³,C]ÖGH:QAF9"-+,/~r8WN1ÀL"-+,0~r8WN/ÀLLÈ
A",C¹T1+LÈ

AQAF9">ZIT>~ÎLNVUEMTM9Þ|JKYú[9¬º@ZH

4QC!
¯"µ.Ä³N)í¢¸»*9­I"ÜM«îL¯ZI:K4èÝMú48W"«µ8WMÄ³
,9á©JúÙI3XQAF!A8A">Z9K±±ªI°A´@Z"^MÄ³'Ä(T^LçÈ#bhj@Z"ÝU"Ä³9I:K4#&Ä³"9U*A"-¯}8Wk&np1'1"9
gqLKYB98ÁL¬º@ZH4QC!
"¸~)9^ý³¢*JAH"~oñGJ Big Data ]ºïAF:ÒvI)Precision Medicine'E³"ÚEr³(*]<ÖA"PD1 ÓXPåMq3JÛ\D")9^*9ýM8W¡ýCYO2=@ZYû¯9¸4J;ê@ZH4QC!EZÍ"TR N:¶MM¡]!ÊCYFSMá
)­&bI">MæÉ]CP:N"%æa]©SFÄ³óaXMtMMï¢JÕ6H4QC!>
M{I"JM±úIT)

Ä³,Cúµõ*M²ZLkÓ'$(AH"öI½U@DHh4H

4YM9Ê5I3XQC!@">Mú4]?±h:"£8W?óùXF4JIAH4QC!
J>[I"tæaIN-++.~L)£"L©A49^¨³"mqe`cj2*]²yA"zØ"W<
Mµ.÷Æ]nA"á¸IN,"+++·z2M^°¤µ.÷ÆIT¯¦{L¦/·>]f6H(HI:"WÜ¦µ.÷Æ'IDEA(LTìA"yWZFCNNHÜÏëøLsÔ#â¬@Z"L<¹¯]¾6WZFJ6wT¤]\4"xpI:Y«¤9RK;GH4QAF!QF"=Ä³§IT"s^dª]Y0LAF GWAS ]¬4F¥®m~oñG"t9Ö#à}ª]Y0LAF HER2 ~oñÊrMG"u Stagev^d9^]Y0LAFà¬ÅñJAH CEA mRNA Âéu%9+e
L9R"ä£ITjhmcofJM«¤]\5>J9I:QAF!zL"£"ÂX]¬4F~oñ
GN"ü?]M tumor cell genomic analysis'TCGA(Li¿CYáJ`§I"tæa9-+,+~8W
ðAF~oñGúµI"DL TCGA Li¿CY_I"áJ`]¦òAF%XORJþAH4
QAF!DL">Mû¯LJMúÀ9A")®LVYþ$mµ.÷ÆM·õ*JË5QjMú[
I"W<Mµ.÷Æ!ôdp&m9¼ã£IwA"VUÞ|K5[L¨GH7XQC!

>F"*ø5õ:Ü@N@C(7Y¢:K2RO-.)L"#Æ,/ùé©¹¥KvÆfK&G2U
NB!vg×Lë°+*~G@C7"ëÚK{»G0~HµJIUN@C7"uJ68âeJ

SUl\Z[7º@F3NB!ÑD"Ïq$GL½òoHúo7j,×"Eo"ÃÅ¨D"ÖÝo"§¯¾«n?7j+×HÊJÔG"vö5Q¡ÕæIn¿F3NB!<K^,G"*L(_ýv³Æ

7Øî>W"kÞ3ÆfJIE

x)K^tX9ªÛBVr¬I&²G2UNBK

G"Äÿ®ôá8"=þüìWM3GB!.A"ëÚH@FQa8Ò8|Ò4äG"c%ûçG8
NBS4¼`_ð"è;BV±ÓG2UNB!
J"+ù_ýv³Æz©¹¤JLÚ7#0`"ÎhåG=Â;á8N@C´Íò3Î]`àLAPjÎ]`KÌÈ'JQ"==ËUÊJ2÷4=?3N@C!NC"#Æ,0ùéKÐã¤G
Lß=Ô)KI6"=<ËKbXU"=­£XUN@CÈ@ï¸yàK!ê1Ç&Õ7$Ùí
·¢'ÌÈHcÚ(Áø*<¶¨Dli
XÀ@º;NB!9ÌÈJL-yó$/KÉCàÌÈJL"¿6TK5>Hm¦

HQ"ëÚKûçKCP"c%K=dH=w;"=ñ"=%BX

UNBS4"s@95p3À@º;NB!
2÷4=?3N@C!
#Æ,1ù-}-+ø

%

#

"

!

&

$

híËeivËeiÜËu[|ØM<ü

µ

É

æ

)

»?¹:R@!

!êâ5V´ÂÕ·[:XDSM"Õ·t×[0¶m+6qëJLW2X%6\N¯yá«.M@X&J12Ö7L×$M@X;JMLWR?D!DE?";YM4@X"23P{¬NòÙ[
@XDSN"{¬M(?1'ô.þ"CNÔ4NTÍHSHmûqJ12ªM?H4WR@!
mû¿O"Èß47?T0WR?DÝW"¦êâN*'5V!êâO+*MÒ3R?D!mûàSÆ
WO-)(éI"CNËeiMmû³1N]`$[ÍH4ÑW?H"ªÌïp";YORAÇÕïp"CN0JÏÕïp".ïpocèJ".J/6ocèJ12U2LÀ[G9HÏÕïp[?H1D
E7R?D!CY[¯?"('(*éMhíËeiv[x¢1D?R?D!Ëei6¹d5V(
×AG6[°õFH"ÄMïp[1R?D!
CNs"!éN;N+N´Â­/¬[Þ?R?D!;Nª5OÍH÷ÁQå%Á[ùGDSM5?"ùÓ?H4WR@!

´Â[­/=YXýM41?R@!
Û~ü

JLX5T?YRB\6"hêNìîvMHìî[411D?R@!T?ìî6ñq

ëI0FDºO"´ÂNø}[SX*ÞI<>1R@!RD"(YDO"CN¨ÿã6\^a_$M¾Ê@X;JMLFH4WR@!
´Â[­/=YDÈÅýM41?R@!
6ö[ìî=YX¤MO"%6\¯yá«.¥Ú´Â&Nú´[çD©[%?H1DE8

U2M411D?R@!¥Ú5VN´ÂNÐzO¡wRII,n*)''"lMLWR@!6\N¯yá«.M&-FH1XTNJ¾§=YR@6"!¥ÚOk¥Úþ½I@NI"!¥ÚN´Â[­9D
I0XJ12;J[%?H1DE8;J6"±,Lf#[TFH4WR@!

£MLWR@6"´Â[­9VYX+$NÈÅý"¡wO!äM4SIJ2<>1R@!!¥ÚN´Â­/[WJ=Y"[MÌM¼SVYXU2411D?R@!
RD"­¸¬[S";NÎÃV?1ÈÅý[<¾Ê1DE7R?D¾Ê¬NyÜ"gyóQ4yóNyóÜ"rÜ"²Ü"b1OðjÜLKNý#M"83»?¹:R@!
c¹"uü[®ZWR@!

" & ( * # ! % $ )'ßô4!+:'Translational Research(.y/>3+6+-#& úÑ   ¢ ò½xaï &&&&&&&&&&&&& Zä{q½W[b"½W[Ñ © » Ü ÷*#l7È1=±o^fýñ8cã&& V Ò && !

N4J1J1)'1693.
E-2P.1*þµ·"7È1=Ý·y}X­¾¥Î?ù+2$Éz && © « p ª && %N4J1'.193CSIQ)
X­
7+A]P.

*¯Ül£¾ý8~`øÃëKACO$D$7k1=Çºr &&  â   && !"5BJ1J1)Ûi{q0.T?@[1*ÆÁm²¤té¯Ül7È1=¹¨£?_à71=2;8 && ¶ Å vÞÿ && !&J>RZGFQ$&%!
Õ6¦nýñ8dû
E-20.

 && "$*£°¡?ö\51=.@À®"ÖXÂ³ù7È1=¸ERQS && Í 
J>J1'1693.
7<=±oøó8cã
0.1;< E-20.

*þ¹¨èàu§³á!í¬ål7È1=JGNPHS)t && Ù  î ´ && "'J>'.J1SIQ)éð¼Ûìùýñ8ÌT%U¿|\D93$&%!

*.@æ©hs?çÔ502j·á]ìá.@7È1=e±Ô && ¾ Ø
OMU8*HJ1ýñ8Ï

ü && #$K(QY1

Ä && $!
*¹¨èà³ãËÐlg7È1=RFPLBIM8õêÚÊ &&  Ó:,=LVF"#93/XWQ),<9Ý·5Y×Çw8ÇºrÛ{qE-2P.

< ` Æ ^ P 8 X T

1/("+!$*)%'.-#&,
s¸½

¯".

&% ëÑ>6à±eOôC\^GQuíLBJ³9Êdª_4U\VPQN>"VªNÆ^GP7<JS]

J9\!SG"ëÑ6eO:9JQÌ©º7<ÒN>N>"ÉÌù0KPæê«Ú<2B9LA]J9\!F@K®
N\ëÑæêP«Ú_P¿BJÌì^G<ÃTZ]J9\<"VªN^GQ#SHJ9N9!%Q GEM$S1$
LV AY^G_°rB"9ëÑà±eOôC\^G(¥n)RÌì^G(¥o)LBJP GSL AY^G
PVªåRqîåOI9J<_±HJ9\!K¥P¢ "e^GPàCO²¤K=\@L_õBG9!

# ! $ "
<µO:?\eP5ÁIâRcâQ5%ð«O8["?tBPÁIâKø3tLNH
J9\!ÉÌW^GPàCOY["Æ^æêQÐ%O«ÚBII8\VPP"eP45çò]QR
6-LUJW©>_K8\!&ëÑ<UzÆT_õK=\Æ^GK8\<"R7P×aQà±BGÜöKÞúA]"·ÆÌPôØONZN9!zF"·ÆÌ<À±A]JVÌ©º7QÒN>N>"·ÆÌ©P45çò]Q1/-$*LMñK=\æê</Z]J9N9!BG<HJ9ëÑaPTNZDÌì
:YRÌ©DÏ^GLBJV^GP>

GCQQ÷=>"Æ^æê«ÚPGUOQ"FP7'Q:[

K8\!

@]SKeOôC\^GPã&N;ÍÆ^SQ Gemcitabine(GEM)K8HG0)!GEM OY
HJVGZA]\çòP|!ªQ"Îà±aKîçò(Overall survival ; OS)ý~û<0/m£;Z02m£"}(xaK2m£;Z5m£L"¡BJMñP9>VPKQN>"Æ^æêP«Ú_P¿BJâó>P`ÓÃ¦<À±A]J=G!5"}(xaO:9J FOLFIRINOX ^G:YR GEM'nabpaclitaxel ^GOY[çòP|!<ÇA](FOLFIRINOX ^G vs. GEM ^G+00#
0m£ vs.
5#7m£"GEM'nabpaclitaxel ^G vs. GEM ^G+7#
4m£ vs. 5#6m£)"KHKVSÄÔ4</Z]
G1)2)!B;B¶á\äWLÕÝÙNMPVÄØP=*<³>"îßÜöP8&_¬N×aO¨
HJY9Z]J9\P<§ÜK8\!
,KQ GEM'S1 AY^GL GEM ù0^GPN¼w8Ã¦OY[ GEM'S1 AY^GPVªå:YRqîå_E´BG3)4)!Npçò(Progression free survival ; PFS)Q|!BGVPP(4#3m£ vs. 2#5m£"p+/#/25)"OS Q-&OVv¹_4UN;HG(02#2m£ vs. 7#7m£"p+/#
0/)!
.ÅO±^]G÷Oø2ïÃ¦KV.XO"PFS P|!Q/Z]GVPP(4#6m£ vs. 3#
0m£"p
,/#
//0)
"OS P|!_ÇC@L<K=N;HG(0/#0m£ vs. 7#7m£"p+/#
04)5)!FPGU",K
Q GEM'S1 AY^GP­Êdªð_õBJ"GEM'S1 AY^GOkabhjl(LV)_ÚÛ

EC\ GSL ^G_°rC\OÂHG!N: S1 NMPgefjiclS»OZ¾è»K8\ LV _AYC\@LOY["gefjiclS»P­Êdª<ðC\@L<üZ]J:["CKOà±÷ÿO:9J S1'LV AY^GPVªå<E´A]J9\6)!
,KQìÆ^bPN99ëÑà±eÈ_ôØLBG GSL ^GPø0ïÃ¦OY["1Ë_0
b&dLB"ø03O GEM0///mg'm2)%éþ"ø0*63O S1 7/mg'm2:YR LV 4/mg _1@C.+÷÷{y¥ Ö1

HOçC[Êw@0P}þ

2[i`fk]?BG!@Pé/áªOQ/3C>ñEA\"à>11-"&Ò_kdj(h>71-L9:®@ÔÖ>ôY\G!SG¸öN7~«Ã+CTCAE grade1)2,LBJí¿0.-"Ç¦)É/1-"'$v=$÷u>5-DIúUY\G!GSL @0QÜ»P FOLFIRINOX @0W GEM)nab
paclitaxel @0L!BJVæÆPN9¶G{>¯A\[t/+à>&FOLFIRINOX @010-"
GEM)nabpaclitaxel @001-,"¡Ï;ÑNMP¸öN7~«ÃP(ò>¿N?+í¿&FOLFIRINOX @024-"GEM)nabPaclitaxel @016-,"ù8Ó>?7ÓLqÝÓPegkaO6\Gi`fkK8[L|'Q;J9[6,!FPGU¤ GSL @0Pé0áª]±¨íK8[+l"UMIN..../.50.,!
û×½ÔÖÄ]5§BJºÜw@0+neoadjuvant chemotherapy : NAC,>ªTY\J9[>"7Nw@0QîSHJ9N9!NAC P5ïPtIQºÜO¶G¹¾]ÎZ"¢®×½+R0 ×½,>]ÄAE[@LK8[!¤21=YPþ$A\J9[c(bQ GS @0]¨BGc(bK8Z"
ÝKñE>Ì^K9[4¥sw!ªKQ GS @0L Surgery first ]!BJ9[!|'Q"GSL@0QXZà><XRù8Ó>9@L=Y"ºÜw@0LBJVÛê©ONZ;[L;J9[!
F@KózKQ border line resectable ÂCOçC[ºÜw@0LBJP GSL @0Pé0áª]±¨
íK8[+m"UMIN..../026.,!
A@=#KFV.,*PJGICW?-M+/
19457<")$%";028:<RUVS.N&LEB%!TOÜ®@PN9#×½ÌH²]çÃLBJ"GEM$S1$LV ,9@0PqÝÓR7Ó]%x
C[!
&!EB630<ë¨ÙOX[#çÁé0áBÀª
'!Q>DT´:%x5%4âpÕå*­%x5%¶G{+à>R Disease control rate,"ÝÕå"7~«Ã
(!MH
2ªPçÃ²Q"ñE¬OrvPð¼]3äC[²LC[!
/,Ü®@PN9#×½ÌH²0,&<ßÅïOH+ÚVB?QÚF-Ä",LËìA\[²1,ECOG P Performance status+PS,%.*0P²2,ûD>0.£rÄP²3,ØµyüN²4,Õ<ïOè³ü"õO¡Ï""Í"ÈP±°ãü>·+O.G\J<Z"2ªñEÜ/3ør÷Pc(b>rvP¼]3GBJ9[²!
lýÐ%1"...)mm3rÄmíÐ%/"
3..)mm3rÄnÆÞA%7#.g)dl rÄo¾ÿÐ%/.."...)mm3rÄ

: V  ì H 7 N L

3j¶adeag%²­¤Á£H0Óos
kGOT'GPT%²­¤Á£H2Óosl® Cre%²­¤Á£H.#2Óos
m§É©Gï¡£ãÀEFRq¤:F84*/ho£H¯º:}½=SRz
5*Ý¨OQÜ

DHÍp:ÎPSC8Rz

"!-5(&')¿.ÐâG GEM UÌæ"¿.Ðâå¦9P¿5ÐâÃ¦KD S1$LV UÏÚ?R!<H/{
U.[&\E>C1[&\?R!2[&\oGB8CI"¸E>CòH·¾"Ô:ÑMPS
RKD¹?R!)©.*#!

&!
" GEM 04
GEM I¿.ÐG.---mg'm2U0-Û9;CÈÅ°Â?R!
&!
# S1 04S1 I»×á±GT@CH|íE>".Ð/wÃ$å¦GÌæ?R!)©/*
/12-

,)*+5

.#
/2m ßÞ

1-mg'w

2.#/2m o£(.#
2m ßÞ

2-mg'w.#
2m o£

3-mg'w

2

2

2

#"

&!
$ LV 04
LV I".w/2mg U.Ð/wÃ$å¦GÌæ?R!
&!
%

.03('

¬ÊâÆH´ÌäE>C"^Z`fg3#
3mg JZX_de0mg U¯é¦rªGçv>C0-ÛDÌæ?R!
#!43.61à·n¯º}{UèØuâE>C"i+-#
-2"

î-#
5-"Ëñ}{/1h"bYf&W]c}{3h"¥HìHà·n¯º}{)~àt³*0#2h"ÝìGOQ}½=SRà·n¯º})¼
êt³*2#
2hE²Ä?RE"Õè¢ð«I14ðEFR!<SG2,HÙÇyðUë>"âÖ¢ð«Iµ»D16ðE>A!
$!+,%02/*ÝI/-.0Ò1.Ð9Px=S"/-.3Ò...4Ð"12ð:Ëñ=SC8R!

ýqBÄ<J«vemöêCiÜ

4

GF@#\DLPAC[X.,-/1:468?"S1">029<?WZ$NACGSL%[X/S'QJH&!YUºCýqnMÄ¥@;>"GEM$S1$LV æòöêCð²wE]»²Máf<J!
'!JH730?
É¸BGJàÄ£Ç-¿ø¢
(!VBIYóáfî%R0 ¶ãáfî%¶õõ"üh)¾õwE Disease control rate*"íÜµÃtp"µÃtp"Üñ"ðj¥"Ì$zÜ¤"p"×bÖ±)!RN
Borderline resectable cancer)BRC*A Cºýqn*!OTEMëCÄ¥nD"ÑúB^dCÎksMìÂ<Jn@<J!
,*ºöCA6ºýq-*âô½¨mÍBýq)¹qF;9D¹ûç¦ßq*@¬Ê:KJn.*ºB Borderline resectable cancer)BRC*A @ÝÊ:KJ/*clÏaMð;A6
0*ECOG C Performance status)PS*%+(-Cn
1*Øù8-+^¦Cn"²èDïLA62*{·gÙAn

3*µôÍBÆuÙ"ÔB°"o"®"ªCÁruÙ8äBé=K>7I"ëÑúº,0Ö^ÕCO&N8^dCsMì=;>6Jn!
UÛ|x±%."+++'mm3^¦VÌx±%,"
0++'mm3^¦W|©¼÷%4#+g'dl ^¦
X|¡Þ±%,++"+++'mm3^¦YÀPQRPS%¸³§Ë¦C.Ú^d
ZGOT'GPT%¸³§Ë¦C0Ú^d[|´ Cre%¸³§Ë¦C,#0Ú^d\ªÐ¯Bø¢¦ïÈ@AJ`§8A6
4*-T}^¦CµÃ8tÅ:KJn
,+*ë­GIå?CÒ_8ÓHK>6Jn
+!K[=5;?
~yU@Òñ?5J!

= \ ¢ ô P 7 U S

5"!53,6/R0 ¿®ñ[¦ïà{êMEK"q+-#-2"«ö-#6-"Õø/1p"g_n']dh3p
"²P¢ôP R0 ¿®ñ[1-,"ç¢ôOVXËDZY R0 ¿®ñ[4-,MÀÑFYM"Þï¯÷¸Q/0÷MNY!BZO2,PâÓ÷[òE"êß¯÷¸QÂÉL/1÷MFY!
#!.2-(
ç¡Q/-.0Û.-/2Ù<WDZ"êß¯÷¸PÕø=©óEK8Y!/1¯÷ê=¬Ázô

åÐL7X"ÛÖÐO¦ïà{êP½[ìÑEK8Y!
01

BZRLOrLQìÑ16÷P9I12÷RLÕø=¶S"¦ïà{êL7YéÆt¼ÇQ­¶ú.3#5p"ÔwºúL6#
0pMìÄ[±YõN»¾=ØWZK8Y!RGÍ!Å¡M
×íOÃñ1-,"á¹`oen'lñ6/#
2,M¨ù}=?"/÷O adjuvant surgery =ÜL7JG!sQìÑÕø¸[èGE"/-.3Û...4ÙL.2÷O§¬[|

EG!ç¡Q R0¿®=ËL>N8­¶ú÷[Ê°OEK8Y="..÷(40#0,)L R0 ¿®[Î»EK8Y!
$ ' & %BZRLO~&Q GSL ãîôåPëºMuÂº[ÚEK>G!Ý¿®¶úOÊEKQëæN
mbjoL7X"Borderline resectableA OÊFY¬ÁzôåMEKTëº=£DZK8Y!GSLôåQúµôO;@Yfkc^i$age=ËL>YM:K8Y!
+*

çPv[Cð8GH>"ÈÌNCy[8GH>REGxÏå·=\ªÒ¢ôÏP¤Pä&O³¥´E±ARF!
4).)Burris HA, 3rd, Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit withgemcitabine as firstline therapy for patients with advanced pancreas cancer : a randomized trial.
J Clin Oncol !"%/1-0*.0".664#/)Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364%.5.4*/2"/-..#
0)Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 369%.36.*4-0"/-.0#
1)Isayama H, Nakai Y, Sasaki T, et al : The final analysis of a multicenter randomized controlled trialof gemcitabine(G)alone versus gemcitabine and S1 combination therapy(GS)in patients withunresectable advanced pancreatic cancer(PC): GEMSAP study. J Clin Oncol 29%1-1-"/-..#
2)Nakai Y, Isayama H, Sasaki T, et al : A multicenter randomised phase" trial of gemcitabine alone
vs gemcitabine and S1 combination therapy in advanced pancreatic cancer : GEMSAP study.
British Journal of Cancer 106%.601*.606"/-./#
3)Ioka T, Ikeda M, Ohkawa S, et al : Randomized phase III study of gemcitabine plus S1(GS)versus S1 versus gemcitabine(GEM)in unresectable advanced pancreatic cancer(PC)in Japan andTaiwan : GEST study. J Clin Oncol 29%1--4"/-..#

6>71:039846=<25;-%Koizumi W, Boku N, Yamaguchi K, et al : Phase II study of S1 plus leucovorin in patients withmetastatic colorectal cancer. Ann Oncol 21#-,,&-(!)'('".%Nakai Y, Isayama H, Saito K, et al : A phase I trial of gemcitabine, S1 and LV combination$GSL%
therapy in advanced pancreatic cancer. Cancer chemotherapy and pharmacology 74#/((&+!)'(*"

7 ] Ï n J 2 T O

7+9-,12.:$4"%72(*'03/6&8!#;5)'0àåã)&% óºïóI¦O"ºïu¢ôç¯¡"ºï"íóØu\PºïóØuJJçFr3~.K"0*(1*¿E2W"ÔFÓEK¼Ï7ÏnZF=D´[YX=×$¦À[vìJ£\Ù:VYH3;FR'3!;YK"µrÓEK=[gh%7?VYI93;FSvìýÞ/IUXAó79Ý¬=S>3AQF³4VYX!;YVJb-8\·S>XAQ
I"ºïóØuJÏnI¾RÆg<YXÀ[Út&óE2Xbenjq&AraC'F"öËI2XI¦OÀ[\TsI>D>Xwmapi%Ç¥yÉ&GCSF'F\Ug>X;FE"@JÄÀ[°7µNX;F\jg=A²7]
ÁJ"o\K[H3Aó\¤«=AºïH7ýÞ/\g3Av)¦vì\$JÊúEK,*+-FUWÑÊ=D3X!;
YNE+-qI´BAAó¤«vìýÞ/\g3Av)¦vìJôù\®YÍ7I÷="rÿóFc°ó\E=A!»®K"çqðJ1ø5UMÃJ|5F=fI"c°F³4VYXºïóØuJ@óIC3DR¨<=D39d6E
2X!

# ! $ "ºïvì"_ä¦À[vì5UMv)¦vì\QA=×$¦À[vìK"CÏó$¦ØuJ¼Ï
nZF=Dl<YD3X!

F"v)¦vìK HLA x0¦}MN¦}gh%7?VYH6BAê¶J+*gh%F=DQ=D3X!,*+0F,§_¬ÂE^\I53DK+-***q\44Xv)¦vì7Ñ
Ê<YD5W"ñcðJv)¦vìÑÊ¹FHBD3X!¦}gh%7?VYI93µrÓERvì
GE2X;FSµrÓI¶U=S>3ÛçvìV(ÜÖO&Graftversushost disease#GVHD'JJ
çP97áH3;F6V"v)¦KµrÓI(>X=×$¦À[vìJÛhHvìÀ[d%cFHBD3
X!
vìýÞ/K"Å&ØuÀ[J¼ûIUX½JJiòFobk_qfÀ[J¼ûIUXgh%Jõ2\
a7F=D´[YX!,o²7]Á:eFÿîXÒüæÒJ3Z3ZH!O¶[?7xL7Ig3VYD
3X7"ýÞ/tAóJb-6VµrÓS#è\c>XçqEK=L=LAó\«Õ=AvìýÞ
/7´[YX!=6=H7V"½JK¾RP9Jµ3vì®JÌ]ªyJxCE2W"¬ëJôù\UW±é<?XAQIR"½J\¾à­I>XAQJvìýÞ/JJ7-IHBD3X!ºïóØuJÏ

nI¾RÆg<YXbenjq&AraC'KÀ[Út&óIÄÀ[°\Ð>AQ"öËI2XI¦OÀ[\TsI>D>Xwmapi%Ç¥yÉ&granulocyte colonystimulating factor#GCSF'
FJUgIUW"@JÄÀ[°7µNX;F7Ð<YD3X+','!NA"pâ7IK"óºïóI¦OI(>X>DnZÎI AraC F GCSF \Ug>Xln^mq`nZID`Oõ&k\±é<?
X;F7W¸<YD3X-'.'!$K;YNE//¿sJóºïóI¦OSºïu¢ôç¯¡I(=D"GCSF Ug,o AraC PºïH7vìýÞ/\g3Av)¦vìI53D"½JkJ«á5UM
õ&kJþHGµ3c°ó\W¸=D8A/'(1'!»"gh%7&Â=H3ºïóØuJM7µr
ÓI53D"GCSF \Ug>X;FIUW²7]ÁJ"o\K[H3;FEAó\¤«=AºïH7
ýÞ/\g3Av)¦vìJl\a7F=D",*+-FUW;,w©ßR%OzEÈ=AµrÓºïóØuI(>XAó¤«vìýÞ/JrÿóMc°ó\®YÍ7I÷=A!

);,w©ßR%Oz ¦{ØuB

Õ

8

¢ÖC«<K»¢}h¨¯MÒ6=×¬h*)#,-+,.¾,,8I-+,1¾2GADtC"¸jA×¬hM¢ÖMÐ<K03eDÄq´ÕA»¢M};=;=£0,ÔC«<K00hD±A"Ào´¨¯M;=,-ÔC«<K,.hM«B;@Ê´Cm¦;=!
h¨¯E"©É§&TBI'/Gy"[bW`Zd&FLU',3+mg%m2"¥²Ò\Vb[Nd&ivBU'
4#
1mg%kg"7HF GCSF ÈÒ AraC ,-g%m2A?=!GVHD ÑÌE"TQcV]ad&CSP'.mg%kg 7HF^R[PY$b_[PXb&MMF'.+mg%kg CHJ
hA5K,ÔE"CSP ­¼CHK GVHD ÑÌM?=!=>;"-nÏD¹?=&,'!

.! '-/,1# GVHD 54'$"!%(+&«ÔD¾Õ±k®E1/&Ãf"03)12'"ª±k®E0.#
1kg&Ãf"/+#3)13#
1kg'A5?=!
sEx¢

¢ÁÆ&AML'2Ô"g|£z&MDS'/Ô"Í¢­y¢ÁÆ&CMML'-ÔA5?=!hÆvE"AML AEnrmº½Ç¿&PIF'/Ô"h¨ÎÓ&Untreated'ÔA5?=!MDS wF CMML AE"/Ô9OSTXUdÓÇlA5?=!h:L=×¬D·~ÐpË¡E±k®9-#/.*,+7%kg&Ãf",#2.).#..*,+7%kg'A5?=!G="CD./(Ë¡E±k®9+#
31*,+5%kg&Ãf"+#/4),#
33*,+5%kg'A5?=!HLA µ¶Cu;@E"A"B"DR
M¤{AÂ³;"1%1i°9-Ô"0%1i°9-Ô"/%1i°93Ô".%1i°9,ÔA5?=&Å,'!
3! (+"&%60*'-$2)

9 M k  B 6 G E

9#".2&(' GVHD
|}&Day3'An_AHJj:=,Lq7=,-Ae
OvD@BZXC\B|LF=!e\0++$mm3

S@-.#
0&P",3%/,'@6>=!_r-++++$mm3OvD@BZXCS

@0.&P"//%,++'@6>=&y-'!

!

"

4 e \VC".X:?t_e \)0++$mm3LF=gpB!
5 _rVC"_r_Lli<;"2X:?t__rz)-++++$mm3LF=gpB!
.# +2)'6!$"&*-4'6!%"|LF=,- ,+@[{ GVHD Lu:=!39 GradeII"-9 GradeIII B[{ GVHD @
6>=!D="{ GVHD AY:?C"Qwc,++Ov|:=,,

1@u:"09b]^",9~x^@6>=!
$"/,1)83Qwc+8I-3D@AFIK=}oY{L CTCAE ver.#+@U:=!Grade.OvB}oY{C"e\as{,.&,++*'"T,+&22*'"dR,&3*'"n_,

&3*'9FIK=&-'!
5# 0,1(73/%".07!*4!5*4+6
Qwc3A,9n_@"Qwc,-,A,9 GVHD @fj:=!-9Qwc,/N`"-,N`@f:=!|mBWhZXS,3N`&P"-(./N`'@"-B~|C3/*"-

B|C0/*@6>=&y.A'!D="-BfC.+*"-BfjC,1*@6>=!

¥<·¨ÎÐº>KÝAWïÐoËÖÀâ[36C?ÞoË10)$ +*,2!1/*,2"%#!'-2!.'-(02
"&#

&

%

GCSF #3K96F¢;\®»Ð;Ù?XWHAWeg]fk^

xKE6FLêM§ðN}~K96FlÖTV¤ZXF6W!eg]fk^7%L©H@FM"GCSF ç1KTV³'G+(K5W¨ÎÐÚº>[­&¼'M (KìóAW>HKTV"­&¼înæ¢;\®'AraC é(L°­&x[¥RWH£8UXF6W!:Ä´GM"L!wenberg B U;¸õ·Ð¨ÎÐù!',3)1+¬([ÝÈKzìó7%µK GCSF [ëµ#3AW>HG*!ÒÜ5'DFS(;/mK
qã?BW>H[$¦@.("Amadori S U;"¥<·Ð¨ÎÐù!'1,)3+¬([ÝÈKzìó7%µK GCSF [ëµ#3AW>HGØz5;/mKÉÅ@C>H[$¦@F6W3(!('GL$¦
K96FM"«ú$ñ¶ÐÐ¨ÎÐù!9TN¨ÎnÑÇ[ÝÈKzìó7%L-òÖTV4òç1@C;"Øz5"*!ÒÜ5HSKª;ôRUXJ6H$¦?XF9V4("ÊGMzìó[-æH@Cs7%GLeg]fk^7%LÿuMåPDF6J6!Pabst T UM4,2+LÐ¨ÎÐù!

·[ GCSF ²3Hü²3K"="?UK AraC ç19[½4L9H¥29L-K"=zìó7%[¤DCH>Y"½4L9GMª;J:DC;"¥29 AraC GM GCSF ²3
LO7GÑÓ;8¡G5DC>H[$¦@F6W/(!eg]fk^7%M"Ð¨ÎÐù![ßþHAW¨ÎÐÚº>L­&þ,ÉK5W GCSF i`ea%[y@F GCSF ç1KTV­&¼Kìó?B­&¼înæ¢;\®L°­&

x[¥RW>HMÖ¿@F6W;"¢;\®KÝ@F»Ð;ä

6­&GM"GCSF KTVÙÌ?BC¨ÎÐÚº>­&;_kcj%h¾4J<JWv÷Ð;5W>H"eg]fk^7%KTVýÂ±Üº>[TVÃJ<AW>H;ÍÛ?XW>HTV"ë¹Ú­&oËµLÖÀâ7%µK9=Weg]fk^7%;/3G5WHtÔ[6FFèàpwÁLÕ.UM"«ú«öÐ¨ÎÐù![ÝÈKd]jbc´[¤DCx"ëÝÈK GCSF #3[¤Z
J6 Historical Control Hû@F¥6*!ÒÜ5G5V«ú5;ä6>H[$¦@C,+(,,(!GCSF #3
à9 AraC [QoËÖÀâ[36Cr·ë¹¨ÎoË9TN)Æ­&oËGM"¯[qã@FS"0õÒÜ512#
3*"0õ«ú5,4#/*Hûæ8¡JÑÓ[íF6W,-(!?ÞoËK96FS"«ú5LÃ9TNÒÜ5L|×JI¥6/

Ð;ôRUXC0()2(!lÉ"GCSF Leg]fk^7%[QoËÖÀâM"¥<·¨ÎÐº>KÝAW?ÞoËK96FS"0[|×AWv÷Ð;5WH£8UXW!
! $ # "
Ç;Ï;ÃJ<¯;á6;"TBI/Gy"FLU,3+mg&m2"ivBU4#
1mg&kg"GCSF #3 AraC,-g&m2[36CïÐ[@C¨Îø{æÖÀâ[36Cür·?ÞoËM"ÖÀâ=ïÐH6 K `  ? 2 E B

118;ZoTWcgxv=M~6k7uCGI96U|Nw=[4GI"\a?yPOS?]egb>l8;"hn5FAhj>53;zYgJuC9!^X@"df?mi5FAQ_SR?Lp=s}>"zY=[4GIH]egb?tg>:3;DVr8;37{q<2H!
"!

)&Miyauchi J, Kelleher CA, Wang C, et al : Growth factors influence the sensitivity of leukemic stem
cells to cytosine arabinoside in culture. Blood 73$)*/*'0")101#*&Saito Y, Uchida N, Tanaka S, et al : Induction of cell cycle entry eliminates human leukemia stem
cells in a mouse model of AML. Nat Biotechnol 28$*/-'0("*()(#+&Löwenberg B, van Putten W, Theobald M, et al : Effect of priming with granulocyte colonystimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349$/,+'-*"*((+#,&Pabst T, Vellenga E, van Putten W, et al : Favorable effect of priming with granulocyte colony
stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation ofcytarabine. Blood 119$-+./'/+"*()*#-&Konuma T, Kato S, Ooi J, et al : Singleunit cord blood transplantation after granulocyte colony
stimulating factorcombined myeloablative conditioning for myeloid malignancies not in remission.
Biol Blood Marrow Transplant 20$+1.',()"*(),#.&Konuma T, Ooi J, Uchida N, et al : Granulocyte colonystimulating factor combined regimen in
cord blood transplantation for acute myeloid leukemia : a nationwide retrospective analysis in Japan. Haematologica 99$e*.,'0"*(),#/&Konuma T, Takahashi S, Uchida N, et al : Effect of Granulocyte ColonyStimulating FactorCombined Conditioning in Cord Blood Transplantation for Myelodysplastic Syndrome and Secondary
Acute Myeloid Leukemia : A Retrospective Study in Japan. Biol Blood Marrow Transplant 21$).+*',("*()-#
0&Amadori S, Suciu S, Jehn U, et al : Use of glycosylated recombinant human GCSF%lenograstim&
during and//or after induction chemotherapy in patients 61 years of age and older with acute
myeloid leukemia : final results of AML13, a randomized phase3 study. Blood 106$*/'+,"*((-#
1&Ohno R, Naoe T, Kanamaru A, et al : A doubleblind controlled study of granulocyte colony
stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 83$*(0.'1*")11,#)(&Takahashi S, Okamoto SI, Shirafuji N, et al : Recombinant human glycosylated granulocyte colonystimulating factor%rhGCSF&
combined regimen for allogeneic bone marrow transplantation in
refractory acute myeloid leukemia. Bone Marrow Transplant 13$*+1',-")11,#))&Takahashi S, Oshima Y, Okamoto S, et al : Recombinant human granulocyte colonystimulating
factor %GCSF& combined conditioning regimen for allogeneic bone marrow transplantation%BMT&in standardrisk myeloid leukemia. Am J Hematol 57$+(+'0")110#)*&Konuma T, Kato S, Ishii H, et al : Longterm outcomes of granulocyte colonystimulating factor
combined conditioning in allogeneic hematopoietic stem cell transplantation from HLAidenticalfamily donors for myeloid malignancies. Leuk Res 39$.*-'+)"*()-#

Ù!Éæ½GK­>é0ºi]_n%`%J@Wë¼âÿ·©

128>.7:6A$2+@;?4)&'*!(!#-"%<590=,31/µ&°¹+(% Ù!Jí@WÉæ½G­>éi]_n%`%[:U8J@W<HL"«3½GNKùKBQJÈAIð
G5W!ZXZXL"¡ÅÏG8©'KSCC(¸¼âJ76F"Éæ½G'CDDP+5FU'FP(G8"Docetaxel+CDDP+5FU'DCF(G8"6ÀäG8'CRT((¬JÃÉ[¼±?BÙ!N2Ô*ÑJ[íÓJ"9ë¼âÿ·©[Fw?B!ý

GKK©¦[RHJ"Éæ½GæÞ¨è×J7;W Rad1-"p1/"p.-K'ªH"è×÷½G­">¬HKK[ß@W<H[¤?B!ûMÛL214JG5V"<XPGJçÑJKIÎÖ5H
Þ¨è×[@OFÄ?B!PB"IÎÖ5[g%c?"Éæ½GHIÎ-E÷}ºHK¢"è×÷½G­3K>¬[ß?B!9©JTV"ÌCKÙ!+Ê½GK­>éi]_n%`%9:U8HIW<H9î=XW!

# ! $ "
¿óIÎJ76F"Ú±Ù!Jí?F downstaging <÷GÉæG8"5W6LÉæÐÀG89¼±=XW<H9ë6!$L"Éæ6ÀäG8¬JÃÉ[¼±?BÚ±Ù!ÑJJD6F¨
þ[±6"è×÷½G­9ô­G5CBÑJGL">¬9

QFH®G5W<H[:U8J?B-(.(!

|7"Éæ6ÀäG8LÉ¬³1Ñ'ÞKqba}ºHIV"PBÉæ6ÀäG8JGL"=P>P
I;jpo%c%9õ@WBQ/("½GæK½G­>éJE:½GíÓÁKå39

QFÈA

G5W!
$L"Ù!áË+9[@6F¨þ[±CBH<Y"G1&S d^eam]th¯JZW p1/K{
úº4z"7TM LOH [=(ÛKÑJJ$QB!PB SNPCGH JFß?BH<Y"p1/4z7TM
LOH [$QWÑJGL"¥?6ãØì.vöÜ[$QB0(!=UJ"Ù!GL DNA.È¶áòÆ/£LKÂA}ºG5W Rad1-K²'ª92,#.*J$QUX"Ù!KuÜüJZW<H[5´?B1(!Éæ6ÀäG8[¼±?BÑJJ76F"½GæÞ¨+9[@6F Rad1-'ª[ß?BH<Y"Rad
1-BÜÑJGLè×÷ô­ÑJ93#
0*G5CBKJí?F"ÜÑJGL0-#3*G5CB1(!PB$
L"½GæÞ¨+9J7;W p1/"p.-zÕ'ªÑJGLè×÷ô­9"J:6<H[5´?B2(!xÔ8U"p1/)p.- G1&S d^eam]th¯S DNA.È¶áòÆ/¯9"Éæ½GK½G­J?@W<H9:U8HICB9"<XULñ¼âK½GÝàJE:¦G5WBQ"ëÛJGK=UI
W¨Ò9QUXW!
xÔTV"Ù!Jí@WÉæ½G­>éi]_n%`%[:U8J?"«3½GNKù[<»@<H[<÷H?"¡ÅÏG8©'KSCC(J76F9rhsblaf\k©[¤?B!
'&

KSCC K¸¼âJ76F".,,,%-§-#8U.,-/%-.§/-#JÉæ½G'6ÀäG8"CDDP+5FU'FP(G8"Docetaxel+CDDP+5FU'DCF(G8(¬JÙ!áËÉ[¼±?BÙ!N2Ô*
ÑJ!Ù!KáËJL"êKÏJ)?FÑJÛ9ÍI6!AKBQ9©GL"KSCC J¸
?F6Wç¼âJýÑJKÄÇ[yD@W!øÊHËÊ[,-J¾@!
+¡Åïï~  0º½G

7 W ¶ H G 3 O L

13)! ($%&"'#%&&"#$*(((")¡)þ6Q*()+")*¡+)þFÓûFé;SÚÉÄ&½Ä³©þ'7³©9T>ÌJB"p{GÅV;KA=>;ÌJ)'¤%á7àÑóFN1Í*B3SC!9T>ÌJ&zåõtÌJHÉ8'*'ÄÞ¶HC:A"8ºÝH9"|8ºÝH9"CDDP+5FU H9"Docetaxel+CDDP+5FU H9G
4<T67³©9T>ÌJ&]li%_½ÄNM'+'¶AÚÉ&R('7³©9T>ÌJ
,'ÄÞ¶H³©ÞGÓûN1Í*G×¢àÑ7"fkgXn6;,:C:A½Ä¹³³ÛF49TA
4SÌJ&òÃ~#'-'½Ä¦G.FóÕí&àÑó¶H§VM'7@4A4SÌJ
.'Ä¦5È¶H&8ºÝH9"|H9ED'GB>H@UE4!
%!#$ì÷u7:±£JGöMH/ôÚC'í:>ÌJ

&

'

%!"(
)'£Gc^Yn$±£&ÿV&UE4ÕHÏ7FPSï®'*'÷;SÌJVöM:"{GIÊÏ7V¼ü;S!
0'ÌJ:Ï7$½Äµ"K"Ö2"×"¡"ÌJ·2)«
1'¸Ï7$¶HÞIÊ.".á0q"½Äþ".FóÕí&¶HÞ×¢"ÚÉ,:

FPSàÑó¶H§#.Fó.ø'
2'¶H$ÄÞ¶HGýD#"Ä¦5È|H9GB>#ýD">¯%×ç"ß×ç+'ÌJGÄÞ¶HÞ×¢àÑVE4A"¨ Rad-)¨è"¨ p-+¨è"¨ p*)¨èFPS?yàÑ|ÜÒV©4"%¥V-};S!=G"ÄÞ¶HÞG Rad-)"p-+"p*)G%¥C"àÑó¶H§"IÊ.Fów²CGLVØ:"¶H§CæeYZj%[%C:AGsF@4A¢
ú;S!
àÑ¢è&fkgXn6;hmb\"N:8H³ÛFA$Ú9T>Ú3$/<'H"³Û6Q.F
àÑ¾Á½ÆÇFÂ?A"öM#c%a`na%B3S CReS ¿F(ä9T"¿ëëx Ë|#ã¬Fõä"£F9TS!ÌJ7­ÇHöM#c%a`na%F¾Á9T"IÊ.Fóc%a
Hc%a`na%ýF54AðÎðRL
F;S!¿ëëxÜÒG

~#c%aV2FC:A"ÌJ·2HöM)«GLGÐêB

Ë|#ã¬5PI.Fì÷»F54A"Ô>FüQT>?yàÑ|Hc%a`na%Ftä9T"IÊ.Fóc%aCCNFc%a`bdC:AF9TS!

Ø#ùó´ªF:AH"ACCTK ùØrv&ùØrvFAùØrv7ñ9T

S'C£»7âîGÍ"°ÀóØVGo:"¹©;S%!#$ÌJG.FàÑVE4Ap{FÂ4-};S!
)'ÌJG.FàÑ&fkgXn6;hmb\"3S4H$ÚÚ3$/<&HE ÜÒC?yÜÒF@4AC+)<''H³Û6Q KSCC öM#c%a`na% CReS ¿J¾Á9TS!
*'ÁÙ9T>fkgXn6;hmb\3S4H$ÚÚ3V"¿ëëx;S!

Ë|#ã¬JõäÜ(ÏëÅQKµHñ:Àm^_q$`$J>XôÁç¥'¾°¢

14,&¨Ëøø Ô#ð»J42E HE éÛ"4UM¸ Rad.*¸õ"¸ p.,¸õ"¸ p+*¸õJUXGéÛ[¹3!nto]w>BpvhaJ=EL¨ËøøÔ#ð»

F/æ>X!
-&9J49X Rad.*"p.,"p+*0±K6[¨Ëø«÷.7NK7N|+E6¹3!
.&Rad.*"p.,"p+*0±G"îÚÿÅQµ"UÒ7Nÿ~ÀGKW[å>X!
6(5.äó§êKáýJL KaplanMeier @[J2X!+©Käó§êK3JLÉG=E Logrank ¯ý
[J2X!¥<SKûãKASJ Cox K3Vlc$ksjuJUX6T¹3!+©K»K3J
L Pearson K`^+Ø¯ý[J2X!¥<SKûãKASJ Logistic :å[¹3!
8*/$2)#3"'7=!&%+20:$9,$;<A°¢L³Z¶7°¢F1W"óÃPKQ[x3°¢FL1X6"ÁçUW"=ó;YAäõîÚ
%ÂP&Kþ¤[yL>X°¢F1XAS"@Kþ¤J1ACEL"ÁçüKÓ,[K>X!=5="ô
8KÁçJ42E"¾°¢Jö=ETNÝ¼z}[¬?J'ÁçüKÓ,[*Xdeir(%Ó,Ñ
0¹&6D2:G6Hï;Y"@KU3IÁçJ42EL"@K'ÂPþ¤(K

2JD2ETNÝ¼z}KÓ,%ßòÝ¼[R&[*A×F"ÂPþ¤=E2AB8:GG>X%'ÁçüKÓ,[*Xdeir(%Ó,Ñ0¹&61XÁçLTNÝ¼z}KÓ,L8K&!%ì"A°¢J¿>X¥'°¢
L>OE"A°¢NK¿K!2JD2ETNÝ¼z}KÓ,%ßòÝ¼[R&[*A×FA°¢J¿#ÈÁ>X!PA"ÃP[þ¤>XKQF"¥'°¢G=EL¿=I2ÁçL"%ÁçKýJÎCE"TNÝ¼z}KÓ,JD2ELöÐ>X!A°¢L³Z¶7°¢F1W"óÃPKQ[x2">OEW­¡=I2!W­.)E=AÃPG=Ex3AS"1VASEÃPMJK'{èF4UM'{ÑLK.)EÃPFL1X6"²ÞÙ?K=´K"5VW­.9:KÙ?L KSCC ÄC¦%CReS ¨Ë&F;$N="°¢FK°¢ùL#X1ºKQFx2"@K)EJÍ:ú{>X!
14+)*/-,®,*+[TCE"¿Áç5VK#X[ÌO=A!½Ìí#XâL/.0VF1W%5+&"íÕ
VKä¯îÚ[>OEÊ=A!PA"ÕVû¼4KÊTO=AAS"AÙ?"ÇÙ?"ÅQ¬IHKUÒÙ?T>OEj$f=A!à*JÕVâKov$g^\btr[Æ>!öÖ["Ïë FP©"DCF ©"CRT ©K,©J:9"ÏëÅQG;P<PUÒ7Nÿ~À%5,&GKª[3¯&=A!PA"îÚÿÅQµGH³GKª%à+&J42EL"%J49X£K¯&­G'I
J"Grade,KH³6½TR·F"Grade)"*KH³6½T8RF1X:G6,;YA!
*! $#%("),&+'

" & ' ( # ! % $:" 8E;&+.!*(')-,?$ 6<5C%D7@B1>/4:# =91>5C30%A2

15Çî¹×°+O}&Üùªi]^l'_'NDYß«Õí16'#ß«Õí¨%¨NVX"AZSKµâÂz$Û

|;Wü¡BZF¹×°+Oi]^l'_'}NI7J"ß«Õ$ßÍ.NVY validation <9YAL<áBZY!
JCOG55,3)-Áös:VQtøÇîNàDY 5FU+cekogr¹×û½z+ÿL¹û½z+ÿOorfmzñ­*O}"øÇî0úÄòNàDYû½z+ÿP"¹VX¹×N8R=K6YAL<±BZF!EO}"#!OÇî`]ho]rKP"Ô¾{ðM Stages$tøÇîNàDY°+P"¹× FP +ÿ+ÿN£°´¹[«DYþÿ<ôºê°+LCJuæ÷
?WZJ7Y!FGC"JCOG55,3Objap'k~ÒO}KP cStage tKPØÐÞO¤<
ÀB7N6X"VX,Mqdnr<"SZJ7Y3(!EAK"¦#!KP JCOG--,5­LCJ"ÊÇîNàDY¹×zý²Ö+ÿ vs ¹× FP +ÿ vs ¹× DCF +ÿOãtÚñ­<ÊèK
6Y4(!VHJ"#NVX"¿)OÊÇîOôº°+Oi]^l'_'<%W;LMY{ðÎ<6Y!
AZSKN·ÓBZFØÃ.N:?Y-Áö*êvªO~ÒO}"¹×°+OÙÆê°+}<´¹O&Nâ=Mx['9YAL<%W;LMHFFT"#N:?YOi]^l'_'OìO¸(Î<TJ±BZFL9Y!
! $ # "
#P"¢i]^l'_'O~Ò<©BZJ:X"åKP°+}&ÜvªOíéNP¬HJ
7M7!C;C".1«Õ;W215.L78óÅNßÍ.OÃ.<çÓBZ"»¯~Ò<ÊèK6Y!¢
ïë$SKN¥¶~ÒO}<õK=YV8"ì[DDTJ7=F7!
)#NàCJ½Ï[®X"y§äÿË(<\·ê°+§äO³Oþ&N"ÈVX/ÉCÄ@SD!¢U"w=Ý=Ñ,êN[ÌÊCJ7>¼ÞKD!
*&-(Saeki H, Morita M, Tsuda Y, et al : Multimodal treatment strategy for clinical T3 thoracic esophageal cancer. Ann Surg Oncol 20%0.23+3/".,-/#.(Saeki H, Morita M, Nakashima Y, et al : Neoadjuvant cemoradiotherapy for clinical Stage IIIII
esophageal squamous cell carcinoma. Anticancer Res 31%/,3/+4".,--#/(Tsutsui S, Morita M, Kuwano H, et al : Influence of preoperative treatment and surgical operation
on immune function of patients with esophageal carcinoma. J Surg Oncol 49%-32+4-"-55.#0(Saeki H, Kitao H, Yoshinaga K, et al : Copyneutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res
17%-3/-+0,".,--#
1(Nakanoko T, Saeki H, Morita M, et al : Rad51 Expression Is a Useful Predictive Factor for the Efficacy of Neoadjuvant Chemoradiotherapy in Squamous Cell Carcinoma of the Esophagus. Ann Surg
Oncol 21%153+2,0".,-0#2(Ishida M, Morita M, Saeki H, et al : Expression of p53 and p21 and the clinical response for hyperthermochemoradiotherapy in patients with squamous cell carcinoma of the esophagus. Anticancer
Res 27%/1,-+2".,,3#

1 5 6 7 2 0 4 3

17.%Ando N, Kato H, Igaki H, et al : A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5fluorouracil versus preoperative chemotherapy for localized advanced
squamous cell carcinoma of the thoracic esophagus$JCOG9907%. Ann Surg Oncol 19#-/&.+!)'()"/%Nakamura K, Kato K, Igaki H, et al : Threearm phase III trial comparing cisplatin plus 5FU
$CF%versus docetaxel, cisplatin plus 5FU$DCF%versus radiotherapy with CF$CFRT%as preoperative therapy for locally advanced esophageal cancer$JCOG1109, NExT study%. Jpn J Clin Oncol 43#.,)&,!)'(*"

ÝÚÈ¹þÅñMàBZ¨²Ò¼·]|÷MBZETN©êLº²4&N2

18:9,73.?6=+$;!'/1852()>$!'"&%0<#4-1B@%*A
ËÜ

ó8,

&% UA>Oâï(MÈ¹N6ZþÅñMàAH"?[SI¨²éz$´Õ4&<¢\[H=E<DN-
Oü5I6Z!ö"z4&UA>O$´Õ4&NÉ!MWY"ðô4&) }éÒ¼N²4Ô3<ç*]0QH7Z!
@XM\[\[O"º²4]z$´Õ4&I­BZWYU"z4&I­AE%<Ò¼1<£>LZ|÷Ì<6
ZJ¡9E!'°IO"âï(6Z7OÈ¹]õTZþ T4 Åñ]àÂM"ðô4&JAHz$´Õ4&;X
­BZMàAH"z4&;X­BZN²4ÍÑN+xÌ]ÁBZ?J]*éJAHnrgmzãsÙ°])2-#
1Gy I¯¢A"z4&O DCF 4&'DOC&CDDP¢8!z$´Õ4&O FP 4&'5FU&CDDP .---&42mg&m2(&5FU$4-&4-&4--mg&m2(I¯¢BZ!º²4UA>O/±²4IÒ¼|÷ML[P"}éÒ¼]¢8!?[SIM127N¿7]¶ÐAH:Y"§@XM¿7¶Ð]AH'²4&N,Ì]ú{AH"ÇA7²4&N2]*®B!

# ! $ "
ª"Ò¼|÷É¢ÅñMàBZ²4O"·Öz4&)}µ·<ù¸I6Z!v%"Vâï(LKÝÚRÈ¹AH7ZÅñ'T4(MàAHO"MOÈ¹Ú]TE¤ÿÒ¼<¢\[E<DNÍÑOTHü5I6Y"ªIO}µ·NêyOL>¨²éz$´Õ4&<¢\[Z?J<

Þ7!
âèX.(MWZJ"ÝÚÈ¹'T4(Åñ:WQÒ¼ü÷orjÓëu/ÌÅñMàAH5FU'1-mg&m2

day.*2"5*./(J Cisplatin '1-mg&m2

day."5(].7Ez$´Õ4&'3-Gy(]¢7"Ø1O54+"×ØO×ßN00+"0öÎÛ1O/0+I6GEJAH7Z!ÝÚÈ¹'T4(
Åñ¿7MGE¿7IO0öÎÛ1O.1+I6Y"ÝÚÈ¹'T4(ÅñMàBZ²4JAH"¨²éz$´Õ4&OSFSF²4ÍÑOü5I6Z!
ö"ÅñMàBZÇA7²4JAH"DCF 4&<#¥@[H7Z!DCF 4&O"¦2<^erf%íûw]æÆM"stages"t'T4 ]¼>(þÅñMàA"·Ö"»z4&JAH DCF 4&

5FU'42-mg&m2"day.*2("Cisplatin'4-mg&m2("Docetaxel'4-mg&m2(]/b%dL7A0b%d¢86½°<³¯@["~"Ø1O3.#
2+"×ØO/3+"R0 Ò¼7O54#
2+I6GEJ"?[SI¯¢@[H=E FP 4&N²4ÍÑ]â=>ÃZ|÷ÌN6Z²4J¡9X[Z/(*1(!E
F"?N DCF 4&<ÝÚÈ¹'T4(ÅñMàAH¢\[E#¥OL7!
öNz4&V$´Õ²4NÉ!MWY"ÝÚÈ¹'T4(Åñðô4&)
Ô3<ç*]¶TH7Z}µ·J78²4!
'ÝÚÈ¹NÄ¤O"²4­åIOÒ¼ü÷I6ZET"·Ö4&2(3(J78)ÀO.7CM"ðô4&'induction therapy(J78)À]¬.BZ(!\[\[O"?[SIMÝÚÈ¹ÅñMàA"ðôz4&6Z7Oðôz$´Õ4&]¢7"g`rdh%c<òX[Ò¼|÷Jøä@[Z¿7MOÐéM}éÒ¼]¢GH=E!îwNìX4(Npiqdlah_k

LIO"ÝÚÈ¹ÅñMàAðôz$´Õ4&Iº²4]¢GEAEÄ¤OÒ¼1<13+M
JKSZNMàA"ðôz4&Iº²4]¢GEÄ¤OÒ¼1<4/+J78~]òH:Y"5L²4ÍÑ<á@[Z!?[XN²4ÍÑO"6>SINpiqdlah_kLÏI6Y"§Ö=,â«ý2ÍÊûerf% ¾z }? a µ @ O 9 Y T

19NñD]&=?9]K¡<[^]!
/)('$&%"!.æò7SEPÍ¾`ùV])ËõNåCI"{@1>[ôø@1`~­C"ÕÀ}ûMéJËõÕÀ`¢;µ@O;ÒKrÛÒ`¶DAK`9íKC"{/¹Ø@1>[ôø@1`~­C"ÕÀ}ûMéJËõÕÀ`¢;µ@KOkoej{çpß°`¢;!
»='|£9%-úÔä?
*´í'|£9%¦µÕÀ?"0úÔä?"8áqÔä"ôø@1OÞ?"ôø@1OÛÞ¤";±Å"¼½¤,Ä#!,+*0"!)%&',

ÝÉÎèNIF-Æ%'ÙF-Æ%"Bì«2WU(OÎè?ö[^E)ËõO¿!
C')ËõX+)ËõNw)>>]ÄCWU(- AÂíNæò7SEPNÍ¾`ùV])Ëõ'cT4Ëõ(J"yâïv`"_M:Ä
C!
+)loh× ',"-"."2"4$loh×(ïv>ÒÄCPîKD]?"zOÈOWO
PÀD]!
8t%+)loh×ïvÄCPÀ@7t%¨¥Æ$+)loh×ROó³ïvÄCPÀ@6t%¨¥Æ$+)loh×ROó³ïvÄCPÀ@. -+ªsÆ3+ª65/ PS'ECOG(
0+),ËõNåD]Úµ@?M:!EFC"µ:ÕÀOö[^E÷¯ÕÀ'pT1a"ly0"v0(P}KD]!

1 ) =ZQ)N/¹ØOÃ¹D?M:AK

2 »=âû?.²B^I:]AKðEÚOAÂ§?szOÈ`5ED


x%ÿ .+++sÆ,-"+++65&mm3ë ,"0++&mm3sÆ
Á# ,+4&mm3sÆÊÜÑ 4g&dl sÆû%àilmio®ÖÓÇÆêO,#0þs÷

AST 5LT®ÖÓÇÆêO-þs÷Ðû%Cr ®ÖÓÇÆêO,#
-þs÷

J9\>H

cnbfgoclbkod 1+sÆ'CockcroftGault ·NZ]¬·WC@P¸ãê`<:"LG[>w0`5ED(
ýû%room air J SpO2 40*sÆ3 º3Ï>[ót?ö[^I:]ÄC
#!($&', »=â'ü"Ì"ý""Ð(OuÇNZ\ËõÕÀ©½(û20ÂÁy¶ªÜ´ÍxHÃ?Vº®©XpÓH?VAPIÈG«{êáIsè

+vÌ¹I§Ýx'AB>"¬êHSU¦Þå9âPV×xX®:(,

ÕÀ4V5Jdg`¼HSV½MAJ½Æ±ë-§ÎGäqØ¹IzmI4V±ë.

ÑÛ"£ÐÛ7SLÑµIpÓ¹RiI4V­¹/

Ô|Ó"CT HSUÒPTWVÊÔ}¢4V5JÔ¾j±Xæ?V±ë

0 HBs ç¹±ë
1

ÄËk9ÙÈËFÒPV±ë

"!#$
#!"

$%'&

»F T4 Ã³ÁyI+CX¿ßolF?Vcg]buUÚ;HSU2'*êá("3'*êotà¾êotêá(I5@W8XÇ?V!5@WIH75DQÉì,¥hÏHêXr?V!^[YgX¸*H?!MA"otêáIaf_Z%eX¸+H"otà
Iaf_Z%eX¸,H?!MA"à

¾°

I°

¾êá

ãI»ÇX¸-H?!2"3Iê²JnIÆUF?V!
2$*ê
otà

otà

¾êá

¾êá'FP+RT .)#-Gy(X6!*ê¤é"º®pÓE4WK´Íº®X6!

º®ÙÓE4WK"+êH??N"DCF êáX,¥w=FH+Z%\6!*ê¤é",&1¥hÏH+êXr?V!+ê¤é"º®pÓE4WK´Íº®X6!º®ÙÓE4
WK"êH??O!êJ~Ç>G5!
3$*êotêá

DCF êáX,¥w=FH+Z%\6!AB>"DCF êá*Z%\¤éHÕÀQ>:Jdg`¼I¨¯9ÒPTWG;WK"¡kIÖÅE+êH·O<FF?V!*ê¤é"º®

pÓE4WK´Íº®X6!º®ÙÓE4WK"+êH??N"otà¾êá'FP+RT .)#-Gy(X6!*ê¤é",&1¥hÏH+êXr?V!+ê¤é"º®pÓE4
WK´Íº®X6!º®ÙÓE4WK"êH??O!êJ~Ç>G5!

(! '&$#"%

" & ' ( # ! % $2$ ./;9"DCF ;9#*,)(!+

2% ./804;9*,)(!+

2& 6-7'10:35

21

22

/+óåª]ñKW1HgÇØÿéãjSWHgL`YÈBVç¡ØudYr

#!"

%$('&

AÿéY

äWP:RZYéS>U;>YXäAVäj¸,THg?"¢óå=d]2HióåY9gñKYÿ

ä?V:L`"ÈÞAWZØu6E}2HióåY9gñKW1HgÿéYV8WcMXg!

äñKY2HiW!HgD?6-DhgS9g!
~ñKY¢WóåGR:g]W=:R"¢MÅY_¯b¢Y;jVT*?V:!_L"¢Ó«Wdf"¢LÀ^YÝ~Y{â?VA"RfYUýbá)\MYìÙ?V:"!;:5<8%2.,+n?C}÷%.3-yC}¡%ëPº3Q
=þ¡%2Q
×Øu bÚ%ud­Y/Qú.qj.2,T?G"×Øuud­Ynº?.2,Yïð

J?9gT?G"{mv'j-#. |mv'j+-#/TGRíy÷j"?HgT"`­5-yY(÷.3-y
TVgDT>eÐâGL!
E¶§Z3'Ö·TGR"2Í\rùöYpzq'"2Í2ì"¬£2"2Í\r¦ø¡$(Âupzq'"û|ÊY"ÄrY2Í

upzq'"ÒrÎYWR"0Ô"¨IÖ·jÁOR:g!
#!/1'796C}Ñdf"^ù/5Q..´_SW12y? entry GL!KY:S"uyro'xØu?ÞsaGAZ:
ÕGL06yY;N"7­?.6y"8­?/-yWf[BehL!Qz?35)15+42*É"9èW0.(5y"T4 1î+)¢"2Hi"tc*?03(/(.yS9OL!¸U&Wdg T4 ?05y"wzt#jG
L T4 ?.yS9OL!e¶§³Z"kXíy÷F4º/Q°YYNWaÃn?S9g!
0*exêÖ·Z"àoÿéZSTFhR:L¢b2HiWóåY9gª]ñKW1Hg"JOudºYAÿéYm¼øjµGHgç`RYÖ·S9g!FeW"Dh_SÁihR:Lç¡Øujb
Ú%ud>eÁ;ØuZ"Øu:Y¾¯ù?l.-,@D9fØu±-?ÆNTVgy?9OLYW1G"
òG:ØuTGRç¡Øujud DCF ud>eÑHgDTS"¾¯ùYUúqj>AS@g
Sø?9f"FeWZÿéqj9CgDTWdOR"ÇØS@gíy?0AVgYSZV:>T:;$W

Q@"¶§jÑGR:g!eÖ·S"ç¡ØuTGRY DCF udYm¼ø?je>WVh["Dh_SWØuùü?ZvTFhR@L¢b2HiWóåY9gª]ñKW1G"òG:Øu?rS@gSø?9f"ØuùüY½ïWPV?gaYT¿<R:g!
$ ) ( &
eÖ·Z0AYÏÔ"Y©wYaT"¹Ë_Sæ<WC}?VFhR@R:g!eÖ·Z"²GR5Vg3'Ö·SÞieI"nlsvlzW=¤Fhgd;V³jJ@âGL:T¿<R:g!
4

3e¶§Y¥WEp:LM@"02VEÓj:LM@_GL»Ì7dö?kßAØu¶§Ì7Y®ÛYc&WôÜõGïC_H!

2 6 7 8 3 1 5 4

"

23

!

(%Ohtsu A, Boku N, Muro K, et al : Definitive chemoradiotherapy for T4 and//or M1 lymph nodesquamous cell carcinoma of the esophagus. J Clin Oncol 17$9%#)0(,&)(!(000")%Hara H, Daiko H, Kato K, et al : Feasibility study of neoadjuvant chemotherapy with docetaxel–cisplatin–fluorouracil$DCF%for clinical stage II//III esophageal squamous cell carcinoma. J Clin Oncol29#)'(($suppl ; abstr +'-'%"*%ChiarionSileni V, Corti L, Ruol A, et al : Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer 96#+*)&/!)''."+%Yamasaki M, Miyata H, Tanaka K, et al : Multicenter phase I//II study of docetaxel, cisplatin andfluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology 80$56%#*'.&(*!)'((",%Yano M, Tsujinaka T, Shiozaki H, et al : Concurrent chemotherapy$5fluorouracil and cisplatin%
and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg
Oncol 70$1%#),&*)!(000"-%Seto Y, Chin K, Gomi K, et al : Treatment of thoracic esophageal carcinoma invading adjacentstructures. Cancer Sci 98$7%#0*.&+)!)''.".%Miyata H, Yamasaki M, Kurokawa Y, et al : Clinical relevance of induction triplet chemotherapy
for esophageal cancer invading adjacent organs. J Surg Oncol !)'()"

ÁÆÓÅFORÃÆ4WæÑ#útµGFë:RÕD:¶G)24

68:7)D0$#("*>9!A/?<4F%@#(
3=+-,.%'(;2EC5&1Bî£Ä¸(($ ­½ÝÉÆ¡G°)H,ËEu·4xB/R4"æÑN°)H"ÁÆV5?36C9AçÖ8SR7C
HpàOQ&8SA5=!<GiZe_hH"=P3F8SA0E0!±"íõ"uÆ¡FßØª4ÎV)Î
9=ÎOH"-%ÛêI4÷:R7C4ò?8SA0R!ýBH"uÎOGÆ¡G CRP G±©ïFò?9"¡7»ÜV§?=C7T"ª4Î)ÛÎOOQMÆ¡ CRP G±©ï4©074"z0ED¡1Mx¹CER7C4U3?=&J Surg Oncol 2015'!<7B"ÃÆGÓÅ*~V]ncm%k:R7CB"D¡á4ìB5RC¦1=!w7"\
ljnH NFob V 9"ÓÅ*~VH1R7C4¾8S"ýBMÒ!¿FªÙ\ljnVüE:R7CBÆ¡G CRP
Gf%[VH1R7CV$9=&Ann Surgery 2015'!;H"^bmXdN\ljnVG0A°)D:¶V):R
7CF/R!

# ! ' %
±"íõ"uÆ¡FßØª4ÎV)Î9=ÎOH"-%ÛêI4÷:R7C4ò?8SA0
R!ýBH"uÎOGÆ¡G CRP G±©ïFò?9"¡7»ÜV§?=C7T"ª4Î)ÛÎO
OQMÆ¡ CRP G±©ï4©074"z0ED¡1Mx¹CER7C4U3?=&J Surg Oncol 2015'!
<7B"ÃÆGÓÅ*~V]ncm%k:R7CB"D¡á4ìB5RC¦1=!;H"8P
FQ/yB§?A0RuÁÆG¡7»ÜVÎOVæN9Aþ:R!<GVMCF"Æó^bmXdüEFOR}Î]ncm%kV§0"D¡á¢G(ØVþ:R!w7"\ljnH NFob
V

9"ÓÅ*~VH1R7C4¾8S"ýBMÒ!¿FªÙ\ljnVüE:R7CBÆ¡G

CRP Gf%[VH1R7C$9=&Ann Surgery 2015'!\ljnH"^bmXdC+IA"rßØNäÊ½Añ|EDG2µG4ËE0=L"ÃÆFé9=üE4(B/R!7SFOQ"Õ=E°)D:¶V)B5RC¦1A0R!;H"^bmXdN\ljnEDG¥}ÎµG@VG0A°)
D:¶V):R7CF/R!
# ! & "
Í­½ÝÉ¡G°)H"³"F$EÀQâJ4E8SA0R!"F"uÆ¡5ÈL8
BH"ACTSGC VóÔC9ABqE¢V¾9".Çù½LC8SA0R!¬¡">{`Ya[gXncã@C/U;A"8PER½L)4ì8SR!w7B"u½AÝÉ¿VëÏF9=F
20A"ClavienDindo 3N grade+pÐGÆ¡ª4ÎH"%P"Ö§û"ÁÆ¼CH#J9=D¡ø
x¹B/?=EDª4ÎCD¡Gþ4ô?8SA0R!ýF20A+))*%3P+)*+%F36A½AÝÉÆVº§9=Ö§u,).OVëÏF¡T¤5Fþ9=MÿFB/?=!<GóB"Æ¡ CRP G±©ïFò?9=C7T"ÂRGÖ§ûNª4ÎGB<CH#J9=D¡øx¹B/Q"Æ¡ª4ÎO
QK9TÆ¡ CRP G±©ï4D¡Vø:R(Ø4/R"-:I54B=&J Surg Oncol 2015'!
Ú CRP 'ûCÚ IL6 'ûH0Få:R7C4ðPSA2Q"E23@ IL6 HÂR²9GæÑ

VC):R7C46«8SA0R!7G7COQÆ¡ IL6 GÐÌ4D¡Vø:R(Ø4¾®8S"
7SVH×:R7CBD¡|ö¢VìB5RC¦1PSR!è>"Æ¡5ÈL8CHsERÞK(í´ív ¨¯ Í

8 ^ Ñ y N 2 V R

25In¶%?ZóCLÑyNI8;Z<JJLZ!
fht_jO"þ.LIO\÷WÕ7XÈþ#aá=[ZmrouI2Y"]sú?Z<JI"jsúÇqUº[H3Z!ðIM/?ZÛâ

ëüe_i`_uNaáëÇq]m?ZCSÖ{çM63HTp$LÔM63H>q=

fht_jBoMWY"d¾Z&U'[vLKNâ¶¾^ë8)?

Z<JL:"µ¤¾^ëN³æ"â¶ CRP îéNsú"â¶e_i`_uîéNsú"NN5

à8OSX[ZJ=[H3Z&ðIÑya_jp_uøåcs%j1'!
|M/>HÛâ

Mfht_jBo]¼FC{ç°¥O3QD`¿=[H6X@"BNm¸üUw&

üMG3HO3QDZiI2Z!fht_jMO­E6NîéUy"üJ3FCqfbT2Z!B<I"õ¼|]/íMâ:$Mfht_jBo]¼47T7NpugnUÏ²]¼3"BNm¸üJw&
ü=XMn¶MG3H¯F?Z<JM>C!
QC"fht_jO"\Çq7XÛâ

M«,>CBoOM>3!B<I"CI°¥>H9Ccsq

uM7k>C!csquO|WY]V=[ZmrouJ>Hðt)õ"ý9mrou]V*õ"ºqLK-ÃLþuü]m?Z!½AñÜ]R4ðIIO"csqu8Ûâ8½3J SIRS

ëÇ7X;>"BN;w

N9MGL8Z<J]±3D>C&Surg Today. 2013'!<[O"csquN NFvb

N?×ú·ÇqJ}ü82Y"ðIâ8M6;Zcsqu_ÞycMWYduit%rI9Z<J]hÇzU{çÏ²IOI9C&Annals of Surgery 2015'!<[QI"lÐgèOlI2Z¾ýcsq
uBoN{çÏ²].Ï²*,0|ÖÍ>"3@[NÏ²TBoM¢?ZßKL¾^ëOOS@X7N¸8OI9C!¾ýcsquO"\Çq8æL:"j©M§?Z<Jh:"ÙâñÜNïLD]¬³=AZ<J8I9ZmrouI2Z!+E"½AñÜ]R4½MAÙâUk_qfbë|LKM¾^ë¬³¸8

0I9Zu(=LmrouJ»5H3Z!
XP'-,B9(7>êIOâ¶_ãycM¦f8Ý8>H3Z!>7>L8X"º8^ÅNQNfl%j"
ÚJ{ü7X»5ZJ"ÁÑ!ä¶ÂQneM>Hó¡Ó8XrI2Z!fht_jO"4BoIN
w&üO?IMx=[H3Z8"\ÇqN@M63HòßLÉû8XrI2Z!<[QINÖ{çª²
7Xfht_jBoMWZëS¬³¸Oìi=[ZTNJË\[Z8"4BoIKN<An¶%¸8±ÀSZ7MG3HOZGiI2Z!ðIcsquBoNn¶%¸MG3HO"<[QINÛâðI-)|N¯FITn¶%¨¹OG7SH6Y"ë|ùN)MWYìi=[ZTNJË\[Z!
ÙâñÜú·N¸8Ò=[[P"BNx£OÑyböMT§]o5ZTNI2Z!ÙâbcN±:>"ne!äNÖÍLKMT§?ZTNJË\[BNx£Oô3!QC"}yªÄ=L@TSH"
ú·lÅN#3#BozLK=XLZ°¥28á´?ZJË\[Z!QC"csquO"}ÊØHÑ²INlÐèO]kÌ>H3Z8"19L$õJLZTNJË\[Z!
C ? A :%!RIN@UC?)+,LD CRP GFT(XD*S=WDVJ<HC?
1Æ1ê}YIÖÍ>C+))/P*®WY R0 !ä]¼FC*)))(*.))|]/íM|â¶ CRP 6Jn¶JN}ü]¶bÎÿ?Z!
&!015.3)+,MK/625"4)+,XD;OE9*QIN@UC?#8$
ðIIO"?IMfht_jMWZïñÜNduit%r]â:¶N SIRS duit%r]k=M¼FH6Y"ïñÜNsú¸MG3Hm¸ü8Ò=[H3Z!~bI"ÂQne¸MG3HO¯F

¹ÁÌ¼NUXºÁ<\ßÊ$îs¬/NãBXÎ-(­Où

26@YJ8M8<ýÂìN®/@YJ8XÉKP%,ìO3Å´PõA8!v&"tKP"Áèabj^dð.P:?MZYJ:VCÇNíAJ8XL±ZYX!¹ÁèOåð.K7X<"tKOoÝÒ[ phase lLAJ·²"á²ÙòLAJ.---4*O)¬qû´[·²BX!

#!@J0>?1)+*,HN&M7.C8-&/;63?YQKlÞ)ð.'ñå]'f/-4*mÞ))¬q/¾+û´1-4&ð./-4*¥ZDJ
1-4OËôºÁO SIRS æ¿NãBX3Å´[·²AG!EYFY"SIRS Oæ¿<ö@YG!QG"/-.4÷.UW"â²ÙK424Ou°¸ó¶¯-ë)¸ÿz£,%¥$Æ
¡}*K7X!?O..24[ãÈN")¨ùÔà)RFS*[é§A")¶1LO Case match control[¢8ûBX!
6 3 A G
.Oâ²ÙòNUX&³ÖP"5!wUW.0034OÆ4O CRFto LEO-[

½×BX?L<{øLMW"Ö[¢9?L<K=G!
/Oabj^dNUXÌ¼úy`kcj'hNUX-Ü¡}OñP"/-.3÷..

ª"ejc`'h¬Ó"ä«äKO IRB Í§[ê~A´P¯"â²ÙòLAJ²ÙO IRBSÐÕèOÉK7X!
0OËôºÁO_igkð.NI8JP"/-.3÷Pü3Å´[»0A"/-.4÷UW"u°¸ó¶¶LAJ424Oá²Ùò|¶[¯RX-ëK7X!
6 3 5 "!D<B4I63%'(?7 CRP :9F$M7&E2L7K=/;63/--5÷.UW/-.-÷./QKN R0 ØÄ[¢HG pT2 pÏOÃùtÆ4!ÁÛ¶1[²¢AGÆ4
T"rµÒ$òµÒ¾"OÆ4PÄ8GÆ4.0304[ÖãÈLAG!
CRPmax)Á

CRP O©¤ç*Oèxç<..#4mg(dl K7HG?L;V"./mg(dl [ cut off LAJ/

N#>ñAG!
pstage lB(m(n 00(35(23%/2(36(22)p+-#30*LÑ¢ïN¦PM;HG<"¹Áµ)Low CRP%
high CRP*//2%/2.)p,-#--.*"À2/3-%1/-)p,-#--.*ÚÒ¥$Æ.2(4.-%.1-(320)p,-#--.*N¦<VYG)þ.*!
3% CRPmax .%&mg"dl ) Low 0* High 0+04(#CRPmax ,2/1-%%!
'mg"dl$/ @ P b 6 - ; 927

FNHGYCX7,(.I2]\EUSL^Q3 CRPmax 3:5`A5 OS 6M/J=?0$R(")%!
>=,851?3%(>=,851?3'&

4# OVERALL SURVIVALS!SUBGROUP"

69@-2/.;*: 61)0
4$ OVERALL SURVIVALS+'$p&'#''(%"V_dDT HR&(#*($P&'#')(%
80"COX DT27"CRPmax /W_dDT HR (#2->"]\EUSL^Q<>:`A4aK[cBO2-10$Z)"*%!
<$ COX +7!OS"

28

ELOl4R$£_¯E:On­ª

Ff§+# COX %)!OS"

I<"§rB9@Gi£_4,#,)%.#,)Bs|£_40qz4vMP<'¨,(!
+$ '*&(!

"

A9<*+-+´E20@K high CRP pG"¬]D­x©²`A/><7B3M CRP =aQT\X[&Z:O7BG­xeEk®:Oc¦48P<!g¢j±E26O{4R
BG^DOmAF­xe4v~JO7B3M";FnG}0B01O!w"UW[SYELO³uoGUV&X9<H3NA/O4";FydE?0@G«

A/O!CF¡¤"aQ°1O7

B4­xeE?D4O3DC7FuoQh3NE8MDOt¥Qb1@05<0!

@ e Ï d T ; ] X

29

4N8=:FC19<3DOI;E/$@#&)'*+(,"
0GJ7>B6HLMK%A-!.?52
6Ç

Oé/&% A¥ ÓTü@ÿB@"¿iÓA¥S$HaÏdQUðTÑTÍPð!§¢T/SÁWO×A@-?bN
AJ!:S¿iÓTôÚJ@ªÙç¼A@eS$HaÏdCUWKXýOAa+SR<!Á"kNáE@eS_U
Rïód_Hawry|sP©LPÒö8ÎM`dQd¼<"¿iÓôÚJ@ªÙç¼A@eO[øã­SGJÏdCdHaDPO"Ï]dZÉFðTÑTºád[J_HDP@@O;aP»=DTgÜÌµd®FJ!

# ! $ "
1999?

½">VOUA@e@@eËT'1PR`"2015?SUåJSA¥Pæ*EbJ

Ó@13

W3500è"?¢ËTì@77"200èPë®EbN<a!§FÛÅRA¥UA@eT>^I30.dõZaP
Eba!
§TªÙç¼FÛÅRA¥TGØÏdUdQ)y|svñÆd¤Y2ÆM`dQ*P©LPÒöÏdT8ÎM`O;a@1*2*"¿iÓ":S75Ä

áTÓOU;î\ÀMÞT[(SNdQd

M`HaDP@Â=Rl&o@#<!DbWO¿iÓTªÙç¼FÛÅRA¥)NSCLC*S>CaGØ
dQU©LPÒöÏd)<PEbNAJ@"5?ð!bU5,6.PïóUJeO;a3*4*!8>CaPÒödQT_`îd²ßFJÌµPFN JCOG0301Ìµ@¼cbJ !71Ä5*

Ó¬SáTôÚJ@

§ NSCLC d$àSPÒöÏd¬)1`fh~zy|s)CBDCA*)30mg'm 'day"Ö5>¢"202>¢*+©LPÒö)TRT*)60Gy'30Fr*P TRT )<)60Gy'30Fr*¬dDHa|r{'ûÌ
µO;`"ÔaH¾ZU÷ð!§¢)OS*O;LJ!200h@5jEb"10±¸T.¢òSNPÒöÏd¬T OS OT^î@Y_?O;`ÌµUú§.ÊPRLJ)OS .,UPÒöÏd¬22#
4±"TRT )<¬16#9±"HR 0#
68"95.CI 0#47,0#98"p-0#0179*!VÏdU¿iÓTªÙç¼FÛÅRA¥S>CaGØdQTMP»=_ba!
wry|s)fjy|!
"

 NDP PcH*U"noy|s)CDDP*Tê;î\Ý¦;îT¯¶dZ3SVSOCEbJ'2í%TB«ñÆO;`"HOSä9¥"7lL¥"A¥RQ8Ð

SO´4PRLN<a!:SkNáE¥O_¹î@¿<PEb"A¥S><N[AkNáE¥OUù¹b\40.P"Tøã­SDF¿B6*7*"gÜÌµ@çZ_bN<J!I§:$§Tç¼AkNáE¥d$àPF"wry|s+upqip~)NDP 100mg'm2+DTX 60mg'm2"3Ömgj~*dGØdQ
TMO;anoy|s+upqip~)CDDP 80mg'm2+DTX 60mg'm2"3Ömgj~*PDHa'ûÌµ)WJOG5208L Ìµ*@¼cbJ9*!ÔaH¾ZO;a OS S><N13#
6± vs11#
4
±)HR 0#81)95.CI%0#67,0#98"p-0#037*P NDP+DTX ¬OU CDDP+DTX ¬SDV_S/FN<J!DT°^`"NDP Uç¼AkNáE¥S$Hai&u|tkPRay|svñÆP»=_ba!WJ"wry|sUPÒöü¡È`d_F8*"#BT¥ÕOPÒöPTM`dQ@¼cbN<a!
A@eS£FNU"VSOU£Ã_@ªÙç¼FÛÅRA¥d$àSwry|s+xj}qip~+8Î©LPÒödQT'ûÌµd¼LN<a9*!VÌµOUwry|sU80mg'm2"4Ömgj~"©
LPÒödQU0âT60Gy'30Fr'6weeks O·2F"M`Haxj}qip~T`fd120(150mg'm2/&Ç&KþI gÜ³¨pq&ÂÚ!æbW®ãôÁXjì]¥V5JamÙ&nW7 &-Ò¸

30

R¶HHQ>a!LW´X level0'01/mg&m2("level1'024mg&m2(W03W?N1R Grade3W
X0dT\"0R Grade1WX0dT\"XNùVQ)/CÆPR=OMS´GbQ>a!
µNùX Grade3WNùXxMK²^R=OM!4VX>:$_Cxq{~r)ykpioWrÝD}nRWmÙ&nW7&-Ò¸dlÄHQ>a0/(!FWÒ¸RXxq{~rX1/mg&

m2Rº?Gb"iJaykpioWd2/*3/mg&m2R¶HGbQ>a!µNùX Grade3WNùdT\K²^R=`"ø¹Nù'DLT(X Grade2WîKC0"Grade2$3X0C0"1T\_bM!ykpioWöçX24mg&m2SGbM!,½X64.'04&1/"3CR("1Uü322.S?W½CÕGbQ>a!
ÅFb_jì]¥V|pUúÿd|Jaxq{~rS­dmÙ&nX"ÂRmÙ&S1Êi
nSWJÓiCPH>SÀ@_baXjì]¥¡Ú¯VAEaÔ'8ÐWPVU`La
SÀ@_ba!ÂÚ!æbW®ãôÁX¥R]+í°VIMÞ@ÔZdJaFSR"Ô{dxÎHü

W×W¾ìd]M_JFSCWR=aSÀ@"FWéÒ¸dÀHM!
"!

A§âSæ§âd_0"1VÕJ)! ($%&0(Éoò[MX+íòVQXjì]¥R=aSTGbQ>a!
1((ÔCU>ÇÔ@ÛábWW¨ê'51Xyy"BWêXæ(2(UX64ÈìR=`"{~rv1ÊinV^amÙ&nWACU>ê3(ECOG PS /*0R=a4(CÓ"X;1/+24.R=a5(ßgU0¦©Wd|Ja///&mm3!¿=«÷- 0#
4//&mm3!Yµ«÷
- 2#!|}lz
- 8#
/g&dl
!µè\÷
- 0//"///&mm3!µû AST$ALT , 0//IU&l!.zz , 0#4mg&dl
1mg&dl!kfrwkf~n - 5/ml&min ì!kfrw, 0#
6(Ò¸Ì(V"Ò¸O~WßgU#wCÁcbM»"¡ÚqõB_häV^aJWL_bMê)" '#%&

0(ì6þuê¼¯d|Ja¡Ú
1(­d<&$CT ìw_BU¤×ùXtXX&êd|Ja¡Ú2( IùWàe¥d|Ja¡Ú'JÓùàe¥A^Yva¨¤C4UOWÓùàe¥!9H®ãÔ
V^`Ô{HMSÀ@_baì]OCe]HDXVsOCe-EWakX IùSHU>(
3( IùWàMU¢%ê"mt%b WGRa$ðÖ¡FàMUÃiêd|Jaê
4(nsguÊW*óD}d±2HQ>aê
5(Sc"ÜQ=ªYSïWWùtXÍW=aåù
6(àMUzffj%d|Ja¡Ú7(ýñÖ¡dÃiHQA`"Ò¸ZWËCÆPS[<Gba¡Ú
8(9°£hgnù'HBsAgù(tX:°£hgnù'HCV Abù(UTW¢%êd|Ja
0/(LW4";ECq·¬d*VØÏJaWVbAES[<HM¡Ú#$Part "!'#&%$
64ÈìWÂÚWÛábW®ãôÁXjì]¥êd5ëVxq{~r)JÓ­dmÙ&ÔWÑAD}d³?H"*ù$|½ùW`dÁ?!

; ] µ 7 O 6 U R

,º3ÿ

31

¨.)Primary endpoint*%|ÕÎ$ò1ÎOî""'·Ò&2³OiekmfrO°êí08OËè,#´ÿ¨.)Secondary endpoints*%Ö¤4"-Ø{ÏÚ"ÕÏÚ"/ôÏÚ©"µ7Ì4Grade0}ÇO'·ÒöÙøÅ©

-# ,634±µ7P"Ê.M¶BV8M""'·Òµ7)TRT*PçÉOÄ·()/Gy'Fr'day"0-fraction"3weeks*\27"iekmfrP*½í0(\¬2A""'·Òµ7Jï³M®BY!)±IP"
ï³"'·Òµ7¢Oâ¡S7(P§[C"µ7¼6¢P­\§8!iekmfrOí08Pû¸MPX!>WZEí0ploO¡è28\í0A"ïû¸IOØ8P§[L7!28plo)þ0*P"0plo\ÐèA"ëé0+0gb^rM¿7¸\ì9BY!MTD)«ßÞ8*P"ì

9¸O28ÍðÎ)Dose Limiting Toxicity ; DLT)þ1**Oø4;.'0,+I6Y28plo
JBY!
)iekmfrO28Ðèª*¹ô¸\ÝÆJAE/GOiekmfr+j`nd_co+"'·Òµ7Oà!×±O\¦5
BYJ"öðÎMP¾%Lä~\$8ý3;6Y;"ðÎLKDOÛOðÎPNò1õLTOJ
¦9WZE?J"æáÑWO*½í0(IOiekmfrIO28ÐèP/-mg'm2I6X"DOÛO»IO'·Ò7(JO&2O±\RYJ/-(02mg'm2O28IÐè@ZH7YTO;Ü7?J:W)±IOiekmfrO*½í0(IO.í08P/-mg'm2\®28JAÔØBY?JJAE!
2$ 57)'(%#&'$("!),-.

,-+*

plo.

/-mg'm2

day ."4".2"//"/5"03

plo//2mg'm2

day ."4".2"//"/5"03

plo0

0-mg'mday ."4".2"//"/5"03

2

2% 57.+1/!Dose Limiting Toxicity ; DLT"&0*

àz×"%IO DLT ÿ Pkqhaoµ7¼6ñ:W0-ñ¢QIJBY!
- ñ)£/ JCOG úðÎÿ P Common Terminology Criteria for Adverse Events)CTCAE*Version 1#
M¿FH§8!DLT P}OðÎJBY!
sGrade1O÷Ã$ÂùÃ
t2ñ}ÇÓBY Grade1O¥ãÃ
uGrade0}ÇOöÙvGrade0}ÇOøóÎ¥ãÃÅwGrade0}ÇOüðÎ)¯²µ7Iarhq&oõLTO\Á=*x'·Òµ7;4½\å9HTÌI<L7È©
yiekmfr;3ã0í0À\+E@Cí0I<L7È©

µUËæÔ4+32

Óß³,X9Û.RðI^:ÉèO<Sóy&zìÁªPart "!'#&%$
ó1ì57OSàÕIPSlgprhv`I:"þÒ`?JI25SRðGNlgprhv,5:
Éè&Ã8IO<SF°ã`)I^!
/ÍJ2´B$2*äî¶/6Ä2´B$ê°M"@º-äî"éäî"|éã2
Grade3}ÛS:Éè,í-Ù¶"FACTL `I:J QOL 2($£ýÎ<)JCOG0301ÁªR=B^:ÉèÅOõ(¡S2*äî¶T35."CBDCA,:ÉèÅO¡S2*äîM
T46.O9KJ!ÐKN2*äî¶SYø`40.PG"ñø`65.RçüI^!!V3*"odu%bip`2*"wcr%0#05"xcr%0#
2O2´§ü`³;ëü`GJÜ¶"0JÙSâT1
ìÁªm%kSàÕP"HÙS`Y23SPQ^!23Sù13S}Û?2*@º-äîF_N:JÜ¶">ÅOTF=O9^P¥WMB^DP?O@^!ÌSôK`©¸W"GüÙSâ`25SPçüGJ!
, - + &
2016*1¦S¨QLOS×)`'NÁª`¾GJ(UMIN000021226)!2016*11¦SÃÿO
Part1Stqs1S76»

÷ãS1S?ÅOùO9]"¬ÃÿOTFÂÚT)YN:Q:!
(%úµUÊ`¤<^?·R=:N"?aËSúµUZ"VJ/B\_Q:¬ÈO9^!G>G
Q?\¹VONF_N@JïAS1ÒýÅO<T*USÛ­?9]"µUËSí+R

HJcnj

vf?NF_N:Q:!>¨TO<P:ÉèØÉSÏýÅO`³;DPOJP<úµUË?aËO9KNZ"3R

HN*ÅD+`B¿GJÅO<SN`B¿IU@P²<>RÖÁª`á³ù

O9^!
2016*1¦'11¦O#S,{ÙS26Sù(61-84»)O">ÁªSðÚPQ^75»}ÛSX9Û.?aÙS5S`§%GN:^?"Çã,¶82S"ÎÑ+S1S"«-4A?a1SS£4S?
4þO"¬ÃÿOT1S?pukesÅO`³KN:^!¹®ZþæQËSÙSÏå`³:Áª`|éRá³GJ:!
µUËO9KNZæÔ4+

Óß³,X9Û.ËRðG>ÁªÅOOÆIÏýÅO?"ËRE

GALËS=XÅO°`È¬O@^DP`ñGJ:!
! $ # "
ËREGALËS=XÅO;<`[]°MýRÈ¬GN:AJY"µUËæÔ4+

Óß³,X

9Û.P:;ðÚ`±KJRÖÁªPQKJ?"°ýQC¼P:ÉèØÉ`&Ã8II^>ÁªSÏýÅO°?ñF_^!
*)>¨RïòQ^EÀ`û:N:^"?aÏýÅO¨½öS¢~RÝ[]¯TÞGÛCVI
.

'1)Yamamoto N, Nakagawa K, Nishimura Y, et al : Phase III study comparing second and third
generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III

2 6 7 8 3 1 5 433

nonsmallcell lung cancer : West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28$23%#*.*0&+,!)'(' Aug ('")%Segawa Y, Kiura K, Takigawa N, et al : Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced nonsmallcell lung cancer : OLCSG 0007. J Clin
Oncol 28$20%#*)00&*'-!)'(' Jul ('"*%Sause W, Kolesar P, Taylor S IV, et al : Final results of phase III trial in regionally advanced unresectable nonsmall cell lung cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117$2%#*,/&-+!)''' Feb"+%Dillman RO, Herndon J, Seagren SL, et al : Improved survival in stage III nonsmallcell lung cancer : sevenyear followup of cancer and leukemia group B$CALGB%8433 trial. J Natl Cancer Inst
88$17%#()('&,!(00- Sep 4",%Atagi S, Kawahara M, Yokoyama A, et al : Thoracic radiotherapy with or without daily lowdosecarboplatin in elderly patients with nonsmallcell lung cancer : a randomised, controlled, phase 3
trial by the Japan Clinical Oncology Group$JCOG0301%. Lancet Oncol 13$7%#-.(&/!)'() Jul"-%Fukuda M, Shinkai T, Eguchi K, et al : Phase II study of$glycolateO,O%diammineplatinum$II%,anovel platinum complex, in the treatment of nonsmallcell lung cancer. Cancer Chemother Pharmacol 26$6%#*0*&-!(00'".%Furuse K, Fukuoka M, Kurita Y, et al : A phase II clinical study of cisdiammine glycolato platinum, 254S, for primary lung cancer Gan To Kagaku Ryoho 19$6%#/.0&/+!(00) Jun"/%Mabuchi S, Kimura T. Nedaplatin : a radiosensitizing agent for patients with cervical cancer. Chemother Res Pract. 2011 ; 2011 : 963159. doi : 10. 1155//2011//963159.
0%Sekine I, Sumi M, Ito Y, Kato T, Fujisaka Y, et al : Phase I study of cisplatin analogue nedaplatin,
paclitaxel, and thoracic radiotherapy for unresectable stage III nonsmall cell lung cancer. Jpn J
Clin Oncol 37$3%#(.,&/'!)''. Mar"('%Hasegawa Y1, Takanashi S, Okudera K, et al : Weekly paclitaxel and nedaplatin with concurrent
radiotherapy for locally advanced nonsmallcell lung cancer : a phase I//II study. Jpn J Clin Oncol
34$11%#-+.&,*!)''+ Nov"

34

4Xý½WþäD;?´Èùx¥&ù4XGÜ<SÃä°?*H¢á!*;4-/)<9%"$.36:+1=:!*&7#(,592?>'08Ñè>'&% ´Èùx¥&ù4XµGÜ;BH4X°?I">HÈÔmD01ç3Q"·%GF:TB0F0H4Á
C/S!9HÁWÚø<S?MG"´Èùx¥&ù4XµGÜ<SÃä°?Ï<W¢á<S9D4,H1ä
C/S!!9!.H´Èùx¥&ù4XÌ¼¾BWì;?D9U">H!9ämÈé4¤3@?9D3Q"´ÈùxHùHý½²Û4ØHù4XHmÈéW¤MSv­D;Bí0B0SHCIF03D01zÎW;B"
W~¬;?!,òCI"fZ]g_iG20B"´ÈùxG27Sùý½I"ù4XHhkbÍær"ÜÖùærWÕÅ:=S9D":QG"´Èùx¥&ù4XHÅåGÜ;B"´Èùx°?3C/S¡Ðsy3cid[a`k4|W±<9D4;¿:T?!¡Ðsy3Wê7;´ÈùxWÇ<S9D4"´Èùx¥&ù4XGÜ<SÃ°?Ï<DFRïS{öÈ4±¨:T?!

# ! $ "
ù4XI}4§H4X®HÞupC/R"õ2*-ÆoÀ4ù4XC®+;B0S!ù4XµH

ðâD;BI".È'«Èù³O´Èù³FEH³WÒ³G¯Aµ4Ù09D4/
8QT"ðG"´ÈùxI¸8H°?CIà®äFÈÔmW8;O<09D3Q"ªN°?G=<S¥&¾C/S(%!´Èùx¥&ù4XµH°?4£VTSG/?@B">HÈÔmD01ç3
Q£Hù4X°?GIÝ5FÇ24N?Q:TB0S!
´ÈùxHò"v#0C/SNHIðúÈ´ÈùxDJTB0S4"ðúÈ´ÈùxHd\j#Y^eCI¤:Gù4X4úÊ<S9D4ßQTB0S)%&*%!ù4XÄ?W£1ÀC¤0"é
CÓ<S´Èùx¥&ù4XHµ4"À»HP1F95C4X°?4·%GF:TB0F0H4
ÁC/R"9HÁWÚø<S?MG"°?Gó¹<S´Èùx¥&ù4XµHÄ?K°?ÉËW
À:=S?MHÃ?F°?Ï<W¢á<S9D4,HäF1äC/S!
´Èùx¥&ù4XH@tG20B"´ÈùxDú4XDHCO"ù4X°?GC;?
´ÈùxÈÔmv­HîãG<SI)¦:TB0S4+%,%"´Èùx¥&ù4XHÊ$äð
È>HNHW0Q3G<SI"9TLC)¦:TB0F3@?!>9C>HÊ$äðÈW÷n<S?MG"!9!lH´Èùx¥&ù4XÌ¼¾BWì;?D9U"ü¥&ù4XDû;B"hkbÂ¶44qGÙ6ôMQT?$ÿ(%!ù4XG20B"/

Â¶IAFº©ú6×v­C/

R "9TI´Èùx¥&ù4XH!9ämÈé4¤09DW±¨;B0S!9H9D3Q"´È-%ùxHùHý½²Û4ØHù4XHmÈéW¤MSv­D;Bí0B0SHCIF03D01"ñ
²HÃ;0zÎW;BBW~¬;?!

'ëè(wÊÝ Þu!9. H d  ; - A >35

B# CFC2-2A85E@$&07%G9CF/<3=!16;@.4D@$& vs. A4D@$&"&'!#"%$#"10*!.&$%',()-+.'/2(&(%[ekwWPJMQNR;quC57BL#6 PJM:OSKPILTG_]rn:o4E187"OSKPILTqk[ekwWQ
NRPJMGcl36!OSKPILTo`"(*t}BDPJMw:mVXxy.v?CF"w;mV
Xxy<h908@OSKPILTo`),t}=7v?CF6$j(%!

:# 16;@.*'(+),%>?

(&)%w.H;pgkwUiQNR;YC57BL#6 PJM;aw:"p^PJM~;w.Hb|Z7-E Lewis lung carcinoma cell$LLC%G
pgkUi25Ez{GY36!pgkwUi`+t}:<s\n:f

GYv4E18.7/"('t36

1P¹yOº­?6;{·n¼·1PA¨7Kw­É½B¬¿ACvdh]®k1¶FIL;$(%!§{CÀ(&´>"¨¦·O}Eov¤~DB®kC¶FIL@0<;!

K# In vivo 2;"5?3467:0U%+S'1-RGLS@I<8>-BV$#In vivo 7@":D89;<?5^'/[*6PMA=C1I`
LLC AeW^Tc#Ym¯O²µ6"eW^Tdh°Ã? IVIS Imaging System AHJ"in vivo >dQeZRaAËB­zO.b[eOtÈ6;$(%!
%#KOS[G0(+4[\QJL2![*61BD>TZE!XW[ZE5VR,.4_fU`RWhÂ²{·n`SXb[e$_fU`RWh°Ã'*´¿%A`SX·1P¾x
LLC O·A±·k6"±k'*´¿A
{·n`SXb[eAA

5L;ËO»q6;!_fU`RWhÂ²

5L;Ë?"Vh\g#e?6= PBS O³­A°Ã6;`SX

5L;ËO¸u6;?4M"ËB©25AÁjC¶FIL@0<;GBB"_fU`RWhÂ²{·n`SXb[e>5L;Ë>Cvdh]®kÊ1ÁjA£r6"Vh\g#e`SX>C¢3¶FIL@0<;¨¦·®k1¶FILKH.A@<;$)%!

K$ DFLSA,&(/STHCE.!S'1-=?9MQ@!POSQ@0NJ)*/&#KOS[G1[)3Y_-/UFHN]2![*61BD>TZE!XW[ZE5VR,.4_fU`RWh°Ã·$_fU`RWh°Ã'*´¿%"Vh\g#e·B9L:L0I"¡ls¾OªÆ6;?4M"_fU`RWh°Ã·0IªÆ6;¡ls¾C"ÁjAiSMA ÅÇ10<;!4LIB¡ls¾O"`SXB·A LLC ?k6;?4M"_fU`RWh°Ã·0IªÆ6;¡ls¾C"·1PBdh]¾C"{·nA/-=¡lp®k"¨¦·®kO¥58;$*%!iSMA Å¡ls

A|NKÄ@{¾>,K4?1«IL=-K+%!

1 C i  : , > =37

C" :?DN8+N$-LR')G79>P,!N%1+342FM6!JINM60HB&(.

#"CKVc?/e^GW.D53;SMA hVFZ>@Jg'!c'7Jg/SN6\U)*3
HKEIDFL0?36MSMA x|NSf:"mf:up9~4@P^B in
vitro :kb8a36!HKEIDFL0?36MSMA x|NSf;"1Cf:upB}v256#w*$!

C# :?DN8+OK=E*;/.5SMA QD<G79>P%!N%1>P+A@0HB&(.

$"jQeE<E/dPJgc'7A[XOBL/MHeiT_.&%,!CKVc?Ifc'7Rk09:8Y`=!ca`=Rk'](b124+
]ORhRWc\ZTR9/-7"'%&% )`0?'%&( (`<8:[Y8"nVJLG{UyB
.zqo1gd2A6s[+[:rf1CXlB~t9"YjxQe1C_"e38.J­mqI®¢;47nªdz²ª.J<5Ek¢¼³=x

²ª.Jr<±1"½°»l¢¦<8+92FC'rI¬i47!u=°»<,+9"nªdz²ª.J¾:¶_<[^U£`"¥bª¹§£`¾.0¨@CF7#¯'$!
V$ ^KWA:AUJGYT&2?I-^KW]>QBS"@HOT<FXT&2 vs.UFXT&2##"6<13?/=@'48;>2/:5(-%*)!>$0+97,A:&.waeµ¤·<BDnªdIv5E2;:"nªdz²ª.J<,1E.J=yIº
5E2;.:/E=-It47!V\WLTS^>"'%%)©&%s<¦«ªa=¼µ;49@
9¨f3F7wae|:"nªd=°<oHEhOKRNK^,B?c<5E~¡}¸A"ag{´º}¸I¶5E2;.CF9+E&%$!ª.J=¥ª`ZQ\<X]
MYKP^:nªdp36"nªd<5E¼µ:*EV\WLTS^I¤·4"nªdIv47;2G"ª.J=j[^U£`"ª£`.¶_<º3F7#($!

M% DP;=Z68735491R[)@HOT<1NC*/',+!T&2-LE.\N(0/; ` ¿ @ Q 5 Y V

&

39

'

ÁÚ%Q!"§,3M5]XQRþ&ÚÁÚ%N©S^L6];"þ&ÚÁÚ%Qqe
y&aks¤MR²=P%;`;&ÜD]@N;ñ[^L9\"UG%Q£ùMR"%;`ÞËÏBQ!",1*XQÃPÁÚ%;³.CL6]@N_¥ÈCL6]'2&*(!@Q8P"%;`×@_±7ÑM²6+÷Mæ

D]ÁÚ%³.%;`QÃ;"FQÚç{N67ö:[";`¿@;Å-POB^L6O6Q;¨ÒM5\"@Q¨Ò_ë$D]GWP"¿@P"ÆD]ÁÚ%³.%;`ÃQ×@T¿@ÛÝ_­ÑBE]GWQÔGO¿@á?_¯òD]@N;1¤QôO4ô
M5IG!
1¤!P96L"ÁÚ%P9>]%Q)Í;%;`Q{Ú÷_²W]»NCLú6L
6]N67"AÎ¤QÛPK6Gü¹Z\û6G¸à_"tciulw_96L£ÐC"Á
Ú%P9>]%)ÍR"%;`Qvzoßõ"ìé%õ_èØBE]@N_ÀCG!B[P"®â5ø7PZ\ÁÚ%_Ù«D]@NM"ÁÚ%³.%;`P9>];`QØ±_:ÙD
]@N;M<]Q:_£ÐC"PAÎ

9B^L6]®â5pwqdnmz;¬_ÀD@N;(AÎulwM>ÐD]@N;M<GN°8L6]!
1¤P96L"In vitro Â¦M"rxftbhzø7%Z\ï<CGâ¶0;";`¶0QÕÉ_èØBE]@N;'3C"O9:J"in vivo Â¦P96L"pwqdnmzø7PZ\"Çvzo
ßõ"ìé%õ;:ÙB^G@N:["´ª"ÞË,#ÁÚ%³.(Í¶0%;`ÃPìD]pwqdnmzQïÿø7"XC=Rê¿@NQ.9@/Q|ãÚN6¬Ú_£ÐD]î-åAÎ¾¦
ºQäÂ¨_4¼CG6N°8L6]!¨ÒQÁÚ%³.%;`¿@P"rx&giw&_XG[
D#ÚQ5]¿@á?_óÌM<^SNíCL6]!
! $ # "
1¤Q¢:["®â5_ø7CÁÚ%_Ù«D]@N;"ÁÚ%³.%;`QÔGO¿@asy&jNO\ý]N°8[^G!1¤:[ý[^Gà_"´ª"AÎ¾¦_±7@NM£Ð
CL6<G6N°8L6]!
µªP"1¤Q~_A;6GH<"¤ÊÛ_A½6GH<UCG;`Äô¿@¤·ðQ¡}PÓZ\«CÖCÑ?UD!
( & ) %,(Kawasaki H, Nagai K, Yoshida J, et al : Postoperative morbidity, mortality, and survival in lungcancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 81$..)2"-++-#-(Spain DM : The association of terminal bronchiolar carcinoma with chronic interstitial inflammation and fibrosis of the lungs. Am Rev Tuberc 76$004)11",402#.(TurnerWarwick M, Lebowitz M, Burrows B, et al : Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35$/41)4",43+#/(Matsushita H, Tanaka S, Saiki Y, et al : Lung cancer associated with usual interstitial pneumonia.
Pathol Int 45$4-0).-",440#0(Hubbard R, Venn A, Lewis S, et al : Lung cancer and cryptogenic fibrosing alveolitis. A population
based cohort study. Am J Respir Crit Care Med 161$0)3"-+++#
1(Koo HJ, Do KH, Lee JB, et al : Lung Cancer in Combined Pulmonary Fibrosis and Emphysema : A
Systematic Review and MetaAnalysis. PLoS One 11$e+,1,/.2"-+,1#4009JC<>8KH413=BEI:@LI095F27;DHANM6?G-$Sato T, Teramukai S, Kondo H, et al : Japanese Association for Chest Surgery. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J
Thorac Cardiovasc Surg 147#',&*%''!(&'*".$Maeda R, Yoshida J, Ishii G, et al : Prognostic impact of intratumoral vascular invasion in nonsmall cell lung cancer patients. Thorax 65#'&/(%.!(&'&"/$Lehtonen ST, Veijola A, Karvonen H, et al : Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res 17#'*!(&',"'&$Aravena C, Labarca G, Venegas C, et al : Pirfenidone for Idiopathic Pulmonary Fibrosis : A Systematic Review and MetaAnalysis. PLoS One 10#e&'),',&!(&'+"

< _ Õ p O 7 X T

41?<LJ=78KDE21;$B"(/*.,)+-%NMGC!'&I>#0F9A5%A:@4H63
Ù5',&% Regorafenib PùæRGð¼ÅK+3<_Oeup%ftaxKk8Z]\ï¡UÏO8ÕpgK7\<"DOÍk
N7F[¾Q<;Iâ@MÛ%ë·ª&HFSR'WíOKë<d-LMHJ8\!CORRECT Ò³KPDOKëQ<NñÜÄ<CUZ]"?N`f`ñN:8JhÓìOKµOQ<<¾8Ó<XÀA]J8\!Regorafenib PËNYH
Jç3E`;Z£ßA]F¶"#N:?\ CYP3A4 NY[ôUA] M2"M5 O÷*ØTNWB UGT1A9 NY[ducwxÌY¿A]/á2NHvA]\!àHJ@]ZO½ýP Regorafenib *ØN:8JâlMe^FC@L<iÿA]\!@]ZO:ÏNP:Ï(¬&SNP'<7[D]E]régm8§<XÀA]J8\!$P Regorafenib <=jA]FùæRGð¼ÅK+3<_.-/sN:8J"UGT1A9 O SNP ^hC\Ldv%m/zîO HFSR
OKë<h|N68@L^XÀBF!_ SNPs ^hC\@LKducwxÌY¿G<WB Regorafenib aW"M2 :Y
Q M5 O°2F<N§^¢RC@L<iÿA\!$P Regorafenib *Øt SNPs LhÓì:YQ°2gTF<LO!^cZ;NC\FU(Ðú¥>ûº=Ê²¤^¯BF!_²¤PµÇð¼2K7\<@]SKO®:YQÂ¶O9^NI8JXÀC\!

# ! $ "
ö8M+3<_Oun:YQó}P´è«º^ÖBJ8\VOO1÷KP,0{"å÷KP,/{
LaG¾8ôäKó}BJ8\!_\N:?\+3<_Ouõ¢QÑ]õOó}PD]E]"«ºK
7["Áo<_²¤hxj%NY\/-.3DOi$KPuõPü)K,.{".14"/--ñ&1÷,1{"
51"
4--ñ"å÷,/{"3/"2--ñ'"Ñ]õKVJ<_NÔ8K,/{"2."3--ñ&1÷,0{"/4"3-ñ"å÷,.{"/1"---ñ'L"O;^.HJ8\.'/'!SFùæRGð¼ÅK+3<_OV¨i¶
Pf0-;±û¶K7["aGùæRGð¼ÅK+3<_PBÕ÷×K7\!
©D"ùæRGð¼ÅK+3<_Oeup%ftaxN:8Jï¡»<_ÆK7\ Regorafenib :YQ
TAS102Ohk÷<CUZ]_\KVÍk<GLMHF!Regorafenib Psukbn%iþÆK7[
ÚN°ïø&VEGFR"TIE2'<_:Ï&RET"KIT"RAF"BRAF':YQNç¦&FGFR"PDGFR'NÉkB»Ýw¹^7C\0'!eup%ftaxN:?\ Regorafenib LothqL^M
BF CORRECT Ò³KPüø&
b"yø&
Mø&

&3#
1;± vs. 2#-;±"HR -#44 62+CI -#31(-#61"p)-#
--2/'
"

&/#
-;± vs. .#4;±"HR -#16 62+CI -#1/(-#25"p*-#--.'N:8JD]E]h|O

4<ÖA]F1'!Z"¾Q<;Iâ@MhÓìVXÀA]J:["?N`f`ñN:?\dv%m0zîOÛ%ë·ª&HFSR'WÑ]s^L9â@MíOKë<(>CUZ]"DOKëQ<NPñÜÄ<ÖÃA]J8\!
Regorafenib PUÏq2--#
50OçUÏ¿TKËNJç3E`Y[£ßA]`ltxgr%j%NY\Hv^Þ?\!£ßA]F Regorafenib P#N:8J CYP3A4 NY[÷*ØTK7\ M2"M5 N*ØA]aW)"M2 :YQ M5 <D]E]gmÉk^KC\!@]ZP UGT1A9 NY[ducwxÌY¿^Þ?/á2NHvA]S<3ãC\Ló$A]J8\&ò.'!@]ZO*Ø½ý^Î\:ÏNP:Ï(¬&SNP'<CUZ]D]E]régm8§<XÀA]J8\2'3'!Regorafenib OhÓìOKëNPñÜÄ<ÖÃA]J:["$PñÜN:?\:8I­O~8<hÓ,¸È0[ñ<_²¤hcP êA42

dWa_R^`xêàs§DßähÁuÀÆ§ÏD«Bxá8?0LAl¯Nå?"6MN¦:LÝÀ@Åi@ Regorafenib 3Äá7M<­£ÔÌªÏ·½3OvB10? Regorafenib ¶xê SNPs Aàs§ÏAD²xNÆ8<!
BÈKM<ºNIABàs§"SNPs 1JF»ßÖËÃAD²xNßähÁuÀBr¬:L±
4´®w}Nyp8<!Ù@E6MH@BÈKM<ºAyp»Dw}DtãB>0?
×:L!

/! Regorafenib &0-*5%1(.'('!*+µ§E*()+Ê-

2K*().Ê.

H@B3O}qàÛÒiB? Regorafenib 3Äá7Mç¤}GD

nB¢ÜB?Çg3ÈKM<)(*è@/L!v©×"æo{Fàs§EÂTc[2K8<!às§DVd$]E CTCAE ver. ,#(B¡9ÑmN=<!Ù}B15L SNPs r¬@E Regorafenib ¶xêhÁB10?ÉÙ«B15LPbcÓÃ3)('f¨DIDN°¸8<!Ù}B1
0?Æ7M< SNPs N¿:L%Ð)&!z×B10?0;MD SNP B10?IßähÁuÀj~3×7M?0L!DNA EÚ¥Î|2K¼

8 PCR B?³Õ"ZQdU\X$USeYØB?´N¾8<!SNPs Aàs§D²xE Fishers exact test Nâ0?r¬8<!
3! 4,)$+2"# SNPs

%

"

#&)$
Ù}DvÍN¿:L%Ð*&!Êé»k¹E.*"Performance status EtC(@/=<!Þ5 H g  ? 2 D B

43,)(?m@Zqtv;"-)(?m>43: KRAS >XGC8!1.(Wp?m>43:l[z@*.)mg%~;298!
1! 2,*%+/#$ SNPs)$%&
c`>43:my5+)(Wp;298\fnGwh7F&,'!j=KU$Q,Wp?k}=\fn@ HFSR&,0#+('"dbVm&*.#/('"u&1#
0('_Ao\&0#
0(';2E^<|{=y;298!
1" 2,*%0&'($3)-.

!"#('
c`>46F Regorafenib si]Yxera?ISTy_ARMPSJTO$N>46FILI

44

fZc_V^`}áÙw¦GØÜm½z¼ÀªCÈªE69QÌ¾SÊy»=Q&Ë/'!ÔBÂOR?UdeÌ¾CU[UªE69QÌ¾H
xFÁ¿B4@?8"ÈªCHlDQÌ¾8ÅLOR?!
<! >43%9)+,$-/0=8&-.-7#*(:7'-/0=8)4/3,#%'!&"(2$6*01$5+
Regorafenib ¶}ám½´CYf%].j§GÙw¦CG±}S=&Ë0'!UGT1A9 IVS1+
399C>T CYf%].j§G HFSR GÉÌ¾EÙkD±}SÅL"Ô SNP SÙ=QCÙkE

ÃD

HFSR GÉ¥8£D5sB4@?&OR +#./"30*CI +#,0(+#12"p)+#+,.'!nÒ"CYP3A4*1G S
Ù=QCYf%].j§Gi¥GÉÌ¾EMÙkD±}SÅL"Ô SNP SÙ=QCÙkE

ÃD

i¥GÉ¥85sB4@?&OR .#0,"30*CI ,#-+(,+#.,"p)+#+-0'!
<" >43%9)+,$ SNPs &?156&';2-.

t$HÄÔªE69Q®¢ÍÇ©É·¹8T¥àE65A"Regorafenib ¶¯B4Q UGT1A96NI CYP3A4 G SNPs CYf%].j§G HFSR 6NIi¥GÉ¥EÙkD±}S¡<?1'!
Õ¨5:CE~7OM UGT1A9 G SNP 8 Regorafenib C²8

LAß=Q Sorafenib E65A

HFSR GÉ¥CG±}8ÅLOR?:C8Ð;RA5Q !KB HFSR É¥G×O7DbW^\a2'

Hu×;RA5D58"Regorafenib G°Þ¤vÉE65A HFSR É¥Ì¾CÛÝCG|EH­G±}8ÅLORA5Q7O"Regorafenib ÖÏpµ6NI>G{¬¶ÎG¸Æ¾8>GÉ¥Eo=QrÇ¬8«³;RA5Q3'!UGT1A9 H Regorafenib ÖÏpµI{¬¶ÎGYeXghÑE}Ú<A6P"Ô SNP SÙ=Q:CBYeXghÑÇEqO7Go8J;RØÎ¸Æ¾8Ï
p=QrÇ¬8«³;RA5Q!
t$H Regorafenib ¶}ám SNPs C¸ØÎÆ¾S³º<"Ùw¦CG}SØÜm½z¼Ó

: ` » 0 O 4 X U

45_,5I$D\?K_%êKBGÝ¶Ôñ×¦;²_BI5\!ÕO CORRECT ·JWæ'þðàÓ(PK Ó):MA]I5\:"'þ÷îK(¹Åú¡NPÚPöVZ]M9H
G-,)!CORRECT ·N8=\ PK ÓJPõ#ÌÃ2O&2,+N85IOUÓ:MA]G!FO-)KBI HFSR _PCV(¹ÅOÝ<:-hcfp%O3*-,õuôNúÃBI5\NW99^ZE
CORRECT ·JP-1õ%NÞO®¿:MA]"~KBI(¹Å_èBGÝ<OÃ29Zhsnp:òZ]M9HG¾B<PÙ'OyJæ'þ÷î:ç|D\MLÃ2ÖãOkcbi:ÍÛA
]\!F?J&PéÇÈàNäD\-hcfp%O D8 N®_¨6¹JM\S<Ý<OÃ29ZÞ_®¿B"§Ngq'j/uÆO(¹ÅúÃºN85IW}øM¢[Þ_®¿D\?KJ"(¹ÅKæ÷îKOÚ_Y[Ä¯N$Z9ND\(ý2)!#NY[ÂóM(¹ÅOúÃKæ'þ÷îKO_$B"§N¹×N(¹ÅOúÃ_*ÛD\kcdo'e'O.:ßA]\!
'! )&%$"#(! $ # "
&P Regorafenib á½3xì´ÝK(¹ÅKOÚ_!ªB"«£"æ'þðà_VGÓ_¨6*éJ4\!ÿ´üê»0:/Ñ_7I5\¡°"gr'kp·

OhmÓY[¥~KtØÏnrlacpNÌÀ­:Ü°D\?K:BQBQ¼¬A]I5\!ÌÀOÐþêMùO­wY[ÿ´üê»0'O(¥ÏRtØÏ_*ÛD\kcdo'e'ú:ßA]\!
'&#NÝâM\@µ{_¸[TBG¤z±å"Ì:`Áê»0±åMZRNvO+NPÉY[½ÊBÆ>\KKWN"«£W#OÎMZRN:`O§M\úëNû1M:Z©
J;\Y6õ&ÒËBI³[TD!
(%-)http : //globocan.iarc.fr/Default.aspx#GLOBOCAN 2012#.,-.#.)http : //ganjoho.jp/reg_stat/statistics/stat/short_pred.html#:`í4$ï#.,-1#/)Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al : Regorafenib(BAY 73
4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine
kinases with potent preclinical antitumor activity. International journal of cancer 129%.01*11".,--#0)Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al : Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT): an international, multicentre,
randomised, placebocontrolled, phase 3 trial. Lancet 381%/,/*-.".,-/#
1)Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, et al : The novel UGT1A9 intronic

8375246<FD:>?1CE9A;@=B

46

I399 polymorphism appears as a predictor of 7ethyl10hydroxycamptothecin glucuronidationlevels in the liver. Drug metabolism and disposition : the biological fate of chemicals 34#())'&/!)''-"-%Miura M, Satoh S, Kagaya H, Saito M, Numakura K, Tsuchiya N, et al : Impact of the CYP3A4*1G
polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12#0..&/+!)'((".%Wakatsuki Tea : Genetic variants of UGT1A1 and 1A9 could be associated with Regorafenib induced toxicity in Japanese patients with metastatic colorectal cancer. Ann Onclol 26#)'(,"/%Lee JH, Chung YH, Kim JA, Shim JH, Lee D, Lee HC, et al : Genetic predisposition of handfootskin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 119#(*-&+)!)'(*"
0%Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, et al : A phase I doseescalation
study of regorafenib$BAY 734506%, an inhibitor of oncogenic, angiogenic, and stromal kinases, inpatients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 18#)-,/&-.!)'()"('%Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, et al : Randomized phase III trialof regorafenib in metastatic colorectal cancer : analysis of the CORRECT Japanese and nonJapanese subpopulations. Investigational new drugs 33#.+'&,'!)'(,"

$"#!*&(')+%! SÅNE+)ý4+*c³×EMD:!

"

?

¹

400¼

.

15

4

+

400¼

. 105

¿Ò$Õ%

105}ü)¿ÒTvqhz*

>+

10~

¨Trmj{cC¸>SÎ"Ü;>¤}T÷>¼"¡æ=QL=:),>Q*c>:",8ARûóTØR<É?D:!15R40¼.40ªOE"ªcN?`K@9@Mtw{pegpEMD:!XJ"CD-ROM"DVD-ROM øRo&nc0ãEJ[Sc"¸>Ã"msp7c8SÎ"ÈR<à_D:!

#=&SÊ&7)+*Tç+¼"7"#7TË+¼N±D:!

$Ö¼T·>Ö¼c>:"õB«ë~T CGS ë~N m"cm"mm"cm2"ml"l"dl"kg"g"mg QP
OEMD:!

% ¿ÒTÂ´}ÎSç?DNÞ8N9`BO"+¼\<c­G`Ï®Tpy&k{iu&r&c=@JÎR8EMD:!
&¨TáOEM/:JEXHd!¿Ò"ÕQPN/c?G`[SRTIS¹8EMD:!

' +T4+ïR>DaJ[SSYc9AMD:!4+ïS>¢ÇRT$­c(EMD:!
( +SÉ?1T½S];RùEMD:!
>+"ðÁ7T3ÔXNE"Ia}ÎT+ä,+et al,OEMD:!
¯+S±¾T Index Medicus Ç±RÅFMD:!
µ»SÏ®/>$­*ðÁ7%E+é7"µ»7"Ö"-Ö)ÙDþ­*ëª4SÏ®/>$­*ðÁ7%E+é7"É7).Á7*"""-"!ªÇ7"!ªî")ÙDþ
­*C

1*ô¥Fí"£§ Ì"ò

9"ä%S@2#O@2 7)12*%108-114"1870#

2*6ü'"ñêÝÿ"¶²

Ñ%°3SßÓì2#gfxl=^°3W)*)

Ð.*"è2""308'327"O@2À"ö"1872#

3*Umezawa H, Aoyagi T, Suda H, et al : Bestatin, an inhibitor of aminopepitidase B, produced by Actinomycetes. J. Antibiotics 29 :86-88"1865#)+úT"TFZRNTFX_"<b_RNV!

*

E+T?¹-TFZR-)åÍ-12-×Ú*-©|-<b_R-+-%-ÕSÛ8-ÕSÆR
¨c¦×EMD:!Õ<]U%RT+ïRÄ`Æ$R$­c(EMD:!

+¬:T½S];Q­c>:XG!
-#

,

((1#

((1*

((a

¨RT%ºc(E"%é"ðÁ7"Çâ"7" ¨5Ö"Õ%óÖc8EMD:!

#-&%()'#.!,$+*"%+*%®÷Ã60#U¶B$Bä$Ì

}0#îAÏ¶Bô:?BaO$#%C$Èö

6³#Óð¶B2Bä$³É

1ý#1¼b,-.0/"$>ÎÇ0#É¶B2Bä$@Ò#q&óf<Þ8$Eh¥#ÌP¶B2?BaO$oc¸üL#¬þ¶B2Bä$Ú 4à#ÌPÊ&VrÞ8$¨ò¥#Ë¶B2Bä$÷ðJNý#U¶B2Bä$ÍN)à#Ãv¶B2Bä$é% ¼Ô#ÌA¶B2Bä$ãÆ#¶u¶B2Bä$

LÉ

#PÊ¶B2Bä$û3®÷Ã60#U¶B$Bä$

3²

üà#PÊ¶B2Bä$#&C$A/ó·x0 #Ìî¶B2Bä$f@¤#Ä¶B2Bä$~É[x#Z×¶B2Bä$À¨Û#îAÏ¶B2Bä$×l»#U¶B§´íg2BaO$

%+*&

y
úÉ
Ë

ØI#¶uá&¤Þ.0/"$ì#óf<¶B2Bä$ºà#ÌP¶B2Bä$#Ìî¶Bm{TÞaO$Îð õ»#1¼2?¶B$t­¢»#îAÏ¶B2Bä$5 ¶#Ìî¶Bm{TÞaO$

É

ÁK#ÌPÊ&VrÞ8$xi

ùà#o¼2?¶B$¾É\6#U¶B2Bä$©7

Nø#]2K¶B2Bä$#'C$ö²40#;y¶B2Bä$X÷Ü#¶æ2?¶B$¡e

pÜ#y#2?¶B$oN|ñ#ÌP¶B2Bä$M

ãÜ#Ìî¶Bm{TÞaO$ÿ,90#ÐË¶B2Bä$¨ç

Ç0#Ìî¶B2Bä$÷²

7à#q&Þ8U,-.0/"$Îe¶Û#¶u¶B2Bä$¯É

n#Wð¶B2Bä$xQ

#N'è¶B2Bä$¹Ñ

#wï2?¶B$%+*'yðxHà#U¶B§´íg2BaO$
%+*(

¶¨

p#U¶B2Bä$÷à#ÌPÊ&VrÞ8$#(C$ªÉ

Yx#;y¶B2Bä$

6ð5dL#¿Ö¶B.2B^$

Es

3ß#q&,-.0/"aO$

!É
e

%+*)

ü#îAÏ¶B2Bä$µD#q&Þ8U,-.0/"$¯yF#Ä¶B2Bä$yÉ

6¥#óf<¶B2Bä$`y#)C$S#kË¶BeÙêÕ2BaO$Â[°#U¶B2Bä$o_¦#Wð¶B2Bä$ÅÚ(#Ga!G=B+ë.0/"$å¨*#1Ý¶B2Bä$!

»#ÌP¶B2?BaO$£à#]2K¶B2Bä$î²jÜ#¶u¶B2Bäâ±GaO«$

¥½#

-

"#zR2?¶B$@2?¶B$

&+*'"0!+$8,-.0/#%$'M%áÛ

&+*(

º*

q

|ÿ$ÜÕJ3Jü%

qá



åá

±:$ÕÕJòÅþõnY­%#È*Ù$^o8,-.0/#nY­%²Ø

GÅ$äZâ8dõ7%

sÀ

¦5$8õ73;.0/#%

Váu¾$ö²3FÕJ%Õ1:$-rBÕJ3Jü%Þ?$äZÕJ3Jü%!1

mí$On!OCJ;%.0/#%¡1 [5$äZÕJ3FJnY­%0Ó

pQ$b¥ÕJÅÔ's3JnY­%W"áÞ>$hCUªÕJ3Jü%e*=.$)3FÕJ%4 "¹$äZâ8dõ7%¢cÏ?$éãÕJ3Jü%áÛ¹Ù$äZÕJ@4òÅþnY­%áÛ

iÄ$NÆ3FÕJ%ÆáT÷$`SÕJ3Jü%ë1 ¾$ZâÕJ3Jü%,$vãÕJqñ$î3JnY­%$aÖÕJ3Jü%

3$ÜÕJ3Jü%\* µ$hCUªÕJ3Jü%8Åø÷$äZ®3FÕJ´CRõ.0/#%öA 7í$ÕÕJ3JüûÒOnYÉ%

Îá

E?$Ý

\

Õ»

xí$AÕJ3Jü%°±÷$Ë5o,-.0/#%§¿$åáJ>"l;ÅÕJ3Jü%w$¬àæÕJ3Jü%

ÕJ3Jü%¯³¹ô$éãÕJ}ÐFJnY.0/#%Eå?$ÕÕJòÅþõnY­%aÖ{ì$ºKÕJ3Jü%*«5$2Úo,-.0/#%å¤$2Úo,-.0/#%=0+?$ä(ÕJy_õnY­%~*$äZâ8dõ7%èÞ$vãÕJqñ$î3JnY­%ÄAß$Õú8Â¾õ.0/#%²* f$ÕÕJ3Jü%X""$(IçÕJ3Jü%t&$Ë5ÕJ3JüðOnYÉ%

Vá

BH$ºKÕJ3Jü%¨¸5$ãÕJ3JüûÒ£DnYÉ%Í1/9$äZÕJ3FJnY­%×Å$Zâú83FÕJ%A¼U$Õú8Â¾õ.0/#%¶áÃ@$hCUªÕJ3Jü%zåÁ$]3FÕJ%°Ì[x$~Ú3FÕJ%LáÙ$vãÕJqñ$î3JnY­%½ê0<$ZâÕJ3Jü%°nì$¨áÕJ3Jü%åÄÙ$äZÕJ3Jü%ØÌ6ô$ý43FÕJ%ÛÓ$*M%1ü

ké9&+*+

6ç$b¥ÕJ3Jü%ß$ý43FÕJ%$)M%?Ó

&+**

ÝÑ

ÛÓ

$(M%Aü

&+*)Ä÷$8-rBõ7j<õ.0/#%Êçø?$gÕJ3Jü%¿¹$ÕÕJòÅþõnY­%©$xÎÕJ3Jü%
lô$b¥ÕJÅÔ's3JnY­%
ß$82';ÅnY­%ù9l$äZâ8dõ7%ï·Ä$ö²3FÕJ%ÿ1

1Ï

D?$äZÕJ3Jü%ÇÌ

A$e*ÕJ3Jü%{$)3FÕJ%P9

$Õú8Â¾õ.0/#%$+M%4

Äó$åáJ>"l;ÅÕJ3Jü%&*)*§Ñ *#1Çj+,-/."i\$#*N$?Ñ

&**%vt#1èÃI3Ið$¸

Ø$#ÃÃI3Ið$«#ýl@'ÃI3Iðó3Ii\$K¸ 4ë#Z(õÃI3Ið$

BÖ

a

µÖ

þã#'+,-/."é6$

Çz#1Çj+,-/."$
ã#_3CÃI¼~3,-/."$

6! Ü#>ê'ÃI3Ið$|§%5#ÙÔÃI3Ið$

É¾

Öü

W#|Ç3CÃI$ÊÑQZ$#_3CÃI¼~3,-/."$¤"²T#ÕúÃI3Ið$y4[ü

tÆ#eâÃI3Ið$<Öoë#Õ]3CCÃI3Iðî½é6$®

ÏØ#]ÒÃI3Iðî½é6$¡w#Ð×ÃI3Ið$#Õ]Ò'cé6$öþ#1Çj+,-/."$#&%N$Þ" ¢#{¸3CÃI$
»

&**&

¿Ñ

}#ÙÔÃI3Ið$!Å¥ë#ÃÃIæ³òéi\$ÈÑÔÍZþ#ÔÃI3Ið$ÑÉ )5#©LÃIái\$Ó^

5f#Î]ÃI3Ið$ÉÔ¹#ýl@ÃI3Ið$©Í%0#û3CÃI$´¾

Â#bÃI³Àùn3Ii\$

H³;#ÕEÃI3Ið$k¨ß#'é6b+,-/."$

ÖüÿÆ#1Ç3CÃI$ºk

Qç#bÃI3Ið$

­Å

T#'

2Ö

ë#1Çj+,-/."i\$

Y

#&&N$

3,i\-/."$

S#bÃI³Àùn3Ii\$¸1#¨ÃI3Ið$d:¦ô#|Ç3CÃI$BÖ!¾t0#Õ]3CÃI$D"ø#RíÃI3Ið$/!

3#qÃI3Ið$ÑÉ-þ#Õ]Ò'cé6$

ô4

ZO#Õ]ÃI3Ið$ª

Ux#Ãì'°¬é-/."$

Ö9"#û3CÃIî½+,i\$¨ë#uÔÃIkä÷à3Ii\$%#Pi!Pi\$p#Ãó3CÃI$åÔ$#ÝüÃI3Ið$Û£#ýl@ÃI3Ið$q±#]Òì'3CÃI$#-Ü0#ýl@'ÃI3Ið$¶Äm#_j'+,-/."$

vß#'+,-/."É=é6$#&'N$Gk¨þ#ÌÃI3Ið$h¤)ß#ËÃI3Ið$

D¾

8Ü#ú&i\é6$XÈ

g#!f2+,-/."$!ü

2ç#ÃÃIæ³òéi\î½é6$

MN

5#úEØÃI3Iðî½Pi\·$&**'`7 -ç#]ÒÃI3Ið$

&**(

Ö

V³#Ãó3CÃI$6ï T$#aÄÃI+,i\$·JÑ¢#©LÃI3Ið$Ó4

Ú- ¨$#Õ]3CCÃI3Ið$´¾

r#ÕEÃI3Ið$A

YFÂ¨#ýl@ÃI3IðéÁ¯ni\·$Ã7

Â+#?ÃI3Ið$s#aÄÃI3Ið$0ð .#ñÔj'3CÃI$¨z#Õ]Ò'cé6$
#Ãì'°¬é-/."$

%++&

&

nL#Á23.417FÓO$-ç¼#jM[¥ÓO7Oÿ$#%&R$gs2#¯JÓOýÌ+£ø;$¬Ù

I#Wo!Wo`ª$q

ó#ßaÓO7Oÿ$>ãÀ¯#aåüB7FÓO$þ

Yï#-MìÓO7OÿýÌWo`Å$ÕÍæãE¯#éaÓO7Oÿ$

u8

JJ#éaåBfø;$ûã

Tú#cpB,-/40"o`ª$ÛÍb9#éa7FFÓO7Oÿ$Qã>##Wo!WCOD)/40"$$Aà#ÓüB»µø/40"$$A³S#aåÓO7Oÿ$.

«[#é-ÓODG7Oo`ª$]ã°ï#3tBÓO7OÿøÑºwo`Å$Ê<

iK#Wo!WCOD)/40"$

ÙãL#B,-/40"Û?ø;$#%'R$Í½ð#aåÓO7Oÿ$AãÈ#e¡ÓO¿Ð,w7Oo`ª$ÄPÀ9#é-ÓO7Oÿ$\Ø]#/7FÓO7Oÿ$

%++'

%++(

#JGpB7FÓO$¬; ×÷#-MìÓO7Oÿ$·0

á#_7FÓO$¾6 r#dÔÓO,-o`ª$ãÛn9#±QÓO7Oÿ$

Þ

×

±ã

Ò#©âëÓO7Oÿ$ùzì»#3tBÓO7Oÿ$°:#ÚòÓOF®7Ol$

ê0 ¢9#Æ?p,-/40"$;P¯ú#Wo!Wo`ª$



]ã

A0

§

#3tBÓO7OÿýÌø;$#ç7FÓO$­#3tBBÓO7Oÿ"7Oo`ª$#%(R$êÜõt#Bhø;$èããÛ

#@ùBÓO7Oÿ$yú#~çÓOsô(ñ7Oo`ª$

H8

#ÓüB»µø/40"$

É#éaåBfø;$vê¤Ë#ßaÓO¿!}Oo`/40"$ê|#ßaÓO7Oÿ$ã

S#jM[¥ÓO7Oÿ$ÛÍ

#ÝÓO7DZ¦ÖXÓOÿ$êã¨#aåÓOÓO;7Oo`F$

16½[#dÔÓO,-o`ª$

U9ó#7FÓO7Oÿ$²

5I#éaÓO7FOo`ª$;Ç

R#e¡ÓOÓO;¶AOo`F$ÃÇ

#ÓüB»µø/40"$

JO íú#e¡ÓO¿Ð,w7Oo`ª$
%++)

<8

#%)R$6é%++*#aåÓO7Oo`F$

bx#^C%ÓO7Oÿ$ÓÇú#ÚòÓOF®7Ol$¬P k8#7FÓOm=7Oo`ÿ7$8½÷#VÂäEø;$ê :#é-ÓODG7Oo`ª$

:

ÏI#

·0

Õ

*9#Wo!WCOD)/40"$

×7FÓO$

nH#éaÓO7FOo`ª$Î@öJI#´îÇpB,-/40"$°Í'~#B,-/40"Û?ø;$N_¸=#I7FÓO7Oÿ$K »µ#~çÓO7Oÿ$]Í¯÷#^C%ÓO¿4FOo`ª$ÂN Ý|#B,-/40"o`ª$´'{9#/7FÓO$ãÛJú#e¡ÓO7Oÿ$#%*R$¹u©9#Ó"7FÓO7Oÿ$DÓ#5×p,-/40"o`ª$

&**(

Óp

¢G#?s?¾=@N$$#&(P$ÚÂo
0;
&**)

¨

#&)P$}pç

­#ÍÍN:N$$¯#Á=m+/364"$

7â

ß¾#Sl!Sl_¥$

5#è/ÍNÍN=:Njl_G$®õ#?+/364"ÚBû=$:#8Â:GÍN$:#è`ÍNÍN=:Njl_G$>7

Aõ#Íÿ?º¶û364"$

é

«#

ª#?û=g+/364"$

1:GÍN:N$$Ñ

àï#Í?ÍN:N$$Úç4Â

x<#è`ÍN:N$$äôo¼ü#è`:GGÍNíRl_¥$÷½ú#:GÍN$ýó

±H#7Øm+/364"$

ÃÒ¢#á>-.,Å×¥:Nl_¥$9ns¼#c:GÍN:N$$Í°

lî#èJÍN:N$$

É;

§#iJ[

ÍN:N$$*#ÍN:N$$8 Aþ#Sl!SDNB-364"$
&***

;°

¢ú#ÍÍNÍN=$#&*P$ÍÎ

#wçÍNoö,ð:Nl_¥$FIÒ9|#wçÍN:N$$

H°:#iJ[ ÍN:N$ÀÕ:GNl_¥$´K<<#`åÍN1052l_¥$âÚ¤#/JêÍN:N$$

}

ß#

æâ

¼Ç#²OÍN:N$$7â

»#è`:GGÍNíRl_¥$

3Ì

¬X#`åÍN:N$$uâÜ#fÏÍN+/l_¥$³I ]A#U!ÍN:N$$\Y

ÐQ#I:GÍN$C7½A#eWÍN:N$$

ãL
'%%%

;°

1:GÍN$##gÍN¾Ë.q:Nl_¥$¼#fÏÍN:N$$#'%P$H7 'þ#?h2û=$]+ ë#iJ[

ÍN:N$$¨¿';#:GÍNÍ^:B364"$

õ#fÏÍN+/l_¥$âÚ{<#`åÍNÍN=$Ú7 #gÍNÍN=$ø7

bþ#Sl!Sl_¥$

%2

®É

é

'%%&

N#è/ÍNFF:Nl_¥$tEï#wçÍNoö,ð:Nl_¥$\âØï#è`:GÍN$

Ê#Sl!Sl_¥$#'&P$)7 rÖ#gÍNÍN=$5#ÙòÍNE©:Nj$\Â#ÍÍNÍN=$è

¢'#iJ[

ÍN:N$$¨D ú#dm?+/364"$KÝaTw#I:GÍN$}a£#è`ÍN:N$"Èû=$âo

y#è`ÍN:GNl_¥$d6

ÛC#/JêÍNÍN=$Þy·#}Øm?ÚBû=$ÚçM#]@(ÍN:N$$

7ç
ÉL
¹
'%%'

µì6´>#è`:GGÍN:NÆ~l_G$â

õ#ÍÍNù¾&ûl_¥$Äz#è`¦:GÍNñµk364"$®ª±#gÍN:BZ¡ÔVÍN$$

2

õv#

Aé

Ä:#I:GÍN$

1:GÍN$¸#?+/364"l_¥$x¢#/JêÍNÍN=$&%%&

M/ ªV#¬ßçÏK9Kû$#&&N$C&%%'À8#Æ9HÏK$`&#dÐÏK/2o]­$!ÛÂ#Ïø7¿¼ö354"$´* µì#§ÏK9Kû$#&'N$»à&%%(®/J#ÖðÏK<¯9Kl$ëshî#Ïø7¿¼ö354"$!:

÷#Ro!Ro]­$)|

2#jAY¨ÏK9Kû${#äÏKö>$I/

Gþ#äÏKÏK>9KÉo]H$

hî#Ro!RFK9%354"$=#e£ÏKö>$þh#_âÏK9Kû$×ä

uÑ ?[#7Òp/2354"$ÁºÂ¢#e£ÏKÄÎ'z9Ko]­$*gÑ±,#7¿;99354"$ïÙ#8;ÏK9Kû$

Þ~#å_ÏK9KûúËö>$ãE

#dÐÏKÏK>$"- O÷#dÐÏK9KûúËö>$òs

=#b9HÏK$ØÑÆ}W#+uEÏK9KûúËö>$?Ä

ÏX#Ï7ÏKÏK>$;·=#å(ÏK9Kû$í/Jî#Ï7ÏKÏK>$Ç* ¤=#ÏÏKÏK>$:´

h#ÒÏK9Kû$Ïå,#Ïø7¿¼ö354"$

§#å_â7fö>$

Bà ,[#Ïø7$#nÉ99354"$

ÕêÊ#»w99354"$

ýD ?.#ÿv9HÏK$æ:Â¼#å_99354"$<*´/

Ãµ#Ïø7¿¼ö354"$^¦

è#cU×BaûP354"$®;

#é:p79HÏK$=#ØÏK9Kû!KûúËö>$#&+N$ñEsn#Ro!1,ö>$@²õ#í*9HÏK$Ý#S¡9HÏK9Kû$«#jAY¨ÏK9Kû$Å#ip7×Bö>$°#7/2354"×Bö>$Ú+¥==#å_ÏK9KûúËö>$µÜ#å_â7fö>$¸Ó

4î#äÏK9Kû!KûúËö>$q²:#dÐÏK9KûúËö>$/

6u#7/2354"×Bö>$LÓ

Z#e£ÏKÏK>$ôÑA¢#+uEÏK9Kû$Õä¶~#Ro!1,ö>$³Ì ##7/2354"åö>$r3:#dÐ9HÏK$Z

áC ±õ#(6ÏK9Kû$#&,N$¸Ó 4î#äÏKÏK>$&%%-Âó#jAY¨ÏK9Kû$¾

#&*N$Íà

&%%,wà

I/ ì#5ÏK9Kû$#&)N$@ã&%%+

j=#å_â7fö>$

tQ

à×

&%%*

`

Èµ#å_ÏK9Kû$#&(N$Ã\&%%)®Ç?>#(6ÏKåö>$Ô=#dÐÏKÏK>$©½0.1#e£ÏKö>$#&-N$!à
ØÑÆ

kY#TùÏKÏK>$*à/¹y#ÖðÏKÏK>$×º

Âì#Ï99354"$

m#å_ÏKÏK>$üûx>#å_â7fö>$\à&#jAY¨ÏK0Kû$
ó#ÏÏKÏK>$

'%&%

Ó

®#Á5DÁL$·¹

GÙ#Ö&q!5DÁL$¢­8#¸üÁLÁL9$Ã

0#+Eq!5DÁL$ÊÏ#k-WÔs

WÙ#ÁÁLÁL9$x +÷#SæÁL5Lè$x<ý#ÁÁLÁL95Llp[D$XÅ;#k-W½8#gÚÁLÁL95Llp[D$ÔÃ+³#!á9TÁ5%021"$

ð³ô#Áå!±®á021"$

ZÏ}y#ÈÁLá9$ZÏ

W#|ÒÁLsÝíº5DLp[¥$

r6

Ñà#ÓîÁLá9$

Bm#îÿÁL5Lè$:ð

##b5DÁL$Mµ+Û#R5DÁL5Lè$Ô}#ï5DÁL$#(%N$¨'%&&#(&N$Ë

'%&'#('N$¦µ

U#+/p[Iùôá9$#\Ðå!5DÁL$ÁL5Lè$
ÁL5Lè$/ö³z#3Äq+/021"Æ=á9$_Í#Áå!±®á021"$

Ã?

­#éuq!+/021"$

ðO§#Ó\Ðn}È5%021"p[¥$©öJÿ#k-W¿ª<#dÂÁL²iKD$

6ªh#ÄÁL^7p[è$@<#eÁLá9$#((N$F

o}#òtA!ÁLÁL95Lp[D$î`¹{Í#ÁÁLÁL95Llp[D$ÏÌ)#Y"ëÁL5Lè$Ò

õã#dÂ5DÁL¼5Lp[¥$

¿]~#v5%021"!Æ+/021"$

ø«¡ì#òtA!ÁLá9$

Q_

'%&(

'%&)

öB

#()N$¦µ
_

'%&*

ÁLá9$

#k-W

ÁL5Lè$

ß#Áå!±®á021"$

L#Áå!±®á021"$¦

4ú#k-W

ÁL5Lè$

U#+/p[Iùôá9$ñsWÙ#¤ÎÕÁL5Lè$¬#ÓîÁLC(5Lp[¥$Ã×

jH#ÄÁL5Lèç¾á9$
ÛY#Á!ÁLÁL95Lp[D$äÏÉ®#>â!ÁLÁL95Lp[D$Æ»ØÃÀ¯#Ó\ÁL5Lèç¾á9$

ÈÃ¹Á8*#éuq!,-.á9$·Û.#îÿÁL5Lè$

Þø

þ#k-W

Ü·

#cVÁL5Lè$#(*N$ÿ6 ,ê#Pµ5DÁL$ÁL5Lè$

Ç

Á$#+/p[Iùôá9$×Ô!a#¶?q!¶?+/021"$µÏ£{#ÁÁL5Lèç¾á9$'

ûw#fðÁLÁL9´óDLp[è$°Ò

+#ÁÁLÁL95Llp[D$6Sw§D2KH+-_

*0+k*, Zv
*0+k+) q

"

q

!

#

o[t

6S{^w§mfts w | 4¢3rQ<E\cC4`33=:G;!
')+-&((.) hpidn)&*/&TUVW+1,-*.&.,0+¨$(+%

Zv~ XjZv
D¤DY2O3ER¡@"xba35BO
CL>?Jx#;O8AE"¦@IMP=rR
7"uz4LF}zDl¥D]CBNG;D@"£I
yDgReI?\93!